



Curated by Peter Lansberg,
a Dutch lipidologist and educator, and
reviewed by prof. Philip Barter, Past President of the
International Atherosclerosis Society.

The IAS statin literature update will keep you up-to-date with all recent statin publications, using a curated approach to select relevant articles.

Statin publications July 2021

Add on treatments

1. Oh PC, Jang AY, Ha K *et al.* Effect of Atorvastatin (10 mg) and Ezetimibe (10 mg) Combination Compared to Atorvastatin (40 mg) Alone on Coronary Atherosclerosis. *Am J Cardiol* 2021; 154:22-28.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34238445>
2. Hou Q, Pang C, Chen Y. Association Between Vitamin D and Statin-Related Myopathy: A Meta-analysis. *Am J Cardiovasc Drugs* 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34296397>
3. Santos Junior GGD, Araújo PSR, Leite KME *et al.* The Effect of Atorvastatin + Aspirin on the Endothelial Function Differs with Age in Patients with HIV: A Case-Control Study. *Arquivos brasileiros de cardiologia* 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34231792>
4. Thiermeier N, Lämmer R, Mardin C, Hohberger B. Erlanger Glaucoma Registry: Effect of a Long-Term Therapy with Statins and Acetyl Salicylic Acid on Glaucoma Conversion and Progression. *Biology (Basel)* 2021; 10.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34208432>

5. Abudalou M, Mohamed AS, Vega EA, Al Sbihi A. Colchicine-induced rhabdomyolysis: a review of 83 cases. BMJ case reports 2021; 14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34290008>
6. Sivasinprasan S, Wikan N, Tocharus J *et al.* Pelargonic acid vanillylamide and rosuvastatin protect against oxidized low-density lipoprotein-induced endothelial dysfunction by inhibiting the NF- κ B/NLRP3 pathway and improving cell-cell junctions. Chemico-biological interactions 2021; 345:109572. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34217687>
7. Woo JS, Hong SJ, Cha DH *et al.* Comparison of the Efficacy and Safety of Atorvastatin 40 mg/ ω -3 fatty acids 4 g Fixed-Dose Combination and Atorvastatin 40 mg Monotherapy in Hypertriglyceridemic Patients Who Poorly Respond to Atorvastatin 40 mg Monotherapy: An 8-Week, Multicenter, Randomized, Double-Blind Phase III Study. Clinical therapeutics 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34332788>
8. Al Salman M, Ghiasi M, Farid AS *et al.* Oral simvastatin combined with narrowband UVB for the treatment of psoriasis: A randomized controlled trial. Dermatologic therapy 2021:e15075. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34327798>
9. Ademi Z, Ofori-Asenso R, Zomer E *et al.* The cost-effectiveness of icosapent ethyl in combination with statin therapy compared with statin alone for cardiovascular risk reduction. Eur J Prev Cardiol 2021; 28:897-904. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34298556>
10. Pareek M, Mason RP, Bhatt DL. Icosapent ethyl: safely reducing cardiovascular risk in adults with elevated triglycerides. Expert opinion on drug safety 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253137>
11. Wacinski P, Gadzinowski M, Dabrowski W *et al.* Anti-Inflammatory Effect of Very High Dose Local Vessel Wall Statin Administration: Poly(L,L-Lactide) Biodegradable Microspheres with Simvastatin for Drug Delivery System (DDS). Int J Mol Sci 2021; 22. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34299106>
12. Patel D, Busch R. Omega-3 Fatty Acids and Cardiovascular Disease: A Narrative Review for Pharmacists. Journal of cardiovascular pharmacology and therapeutics 2021:10742484211023715. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34191622>
13. Kapoor K, Alfaddagh A, Stone NJ, Blumenthal RS. Update on the omega-3 fatty acid trial landscape: A narrative review with implications for primary prevention. J Clin Lipidol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34294561>
14. Tadic M, Sala C, Grassi G *et al.* Omega-3 Fatty Acids and Coronary Artery Disease: More Questions Than Answers. Journal of clinical medicine 2021; 10. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34200081>
15. Laird J, Falk RH, Coyle M, Cuddy SAM. Rhabdomyolysis in the Setting of Concomitant Use of Tafamidis, Atorvastatin, and Amiodarone. JACC Case Rep 2020; 2:2372-2375. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34317174>
16. Choi WM, Kim HJ, Jo AJ *et al.* Association of aspirin and statin use with the risk of liver cancer in chronic hepatitis B: A nationwide population-based study. Liver international : official journal of the International Association for the Study of the Liver 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34242482>

17. Li C, Bu X, Liu Y. Effect of folic acid combined with pravastatin on arteriosclerosis in elderly hypertensive patients with lacunar infarction. Medicine (Baltimore) 2021; 100:e26540. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34260532>
18. Moschetti A, Dagda RK, Ryan RO. Coenzyme Q nanodisks counteract the effect of statins on C2C12 myotubes. Nanomedicine : nanotechnology, biology, and medicine 2021; 37:102439. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256063>
19. Shah PA, Zaidi HA, Syed HK *et al.* Formulation development and in vitro characterization of triple layer tablet containing amlodipine besylate, rosuvastatin calcium and hydrochlorothiazide. Pak J Pharm Sci 2021; 34:699-710. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34275805>

Adherence

1. Cornelison P, Marrs JC, Anderson SL. Clinical Pharmacist Outreach to Increase Statin Use for Patients with Cardiovascular Disease in a Safety-Net Healthcare System. American health & drug benefits 2021; 14:63-69. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34267861>
2. Jaspers NEM, Visseren FLJ, van der Graaf Y *et al.* Communicating personalised statin therapy-effects as 10-year CVD-risk or CVD-free life-expectancy: does it improve decisional conflict? Three-armed, blinded, randomised controlled trial. BMJ Open 2021; 11:e041673. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34272216>
3. Hasan S, Naugler C, Decker J *et al.* Laboratory reporting of framingham risk score increases statin prescriptions in at-risk patients. Clin Biochem 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34197811>
4. Hero C, Karlsson SA, Franzén S *et al.* Impact of Socioeconomic Factors and Gender on Refill Adherence and Persistence to Lipid-Lowering Therapy in Type 1 Diabetes. Diabetes Ther 2021; 12:2371-2386. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34292559>
5. Alefishat E, Jarab AS, Al-Qerem W, Abu-Zaytoun L. Factors Associated with Medication Non-Adherence in Patients with Dyslipidemia. Healthcare (Basel) 2021; 9. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34203226>

Atorvastatin/Rosuvastatin

1. Sun J, Kumar Panda P, Kumar Samal S *et al.* Effects of Atorvastatin on T-Cell Activation and Apoptosis in Systemic Lupus Erythematosus and Novel Simulated Interactions With C-Reactive Protein and Interleukin 6. ACR open rheumatology 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34302321>
2. Zhang XB, Cheng HJ, Yuan YT *et al.* Atorvastatin attenuates intermittent hypoxia-induced myocardial oxidative stress in a mouse obstructive sleep apnea model. Aging 2021; 13:18870-18878. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34289453>
3. Zereshkian A, Wasserman S. Liver enzyme elevation and eosinophilia with atorvastatin: a case of probable DRESS without cutaneous symptoms. Allergy

- Asthma Clin Immunol 2021; 17:81.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34330325>
4. Oh PC, Jang AY, Ha K *et al.* Effect of Atorvastatin (10 mg) and Ezetimibe (10 mg) Combination Compared to Atorvastatin (40 mg) Alone on Coronary Atherosclerosis. Am J Cardiol 2021; 154:22-28.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34238445>
 5. Wang Y, Du X, Zhao R *et al.* Association of APOE polymorphisms with lipid-lowering efficacy of statins in atherosclerotic cardiovascular diseases. Ann Acad Med Singap 2021; 50:474-480. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34195754>
 6. Sivasinprasasn S, Wikan N, Tocharus J *et al.* Pelargonic acid vanillylamide and rosuvastatin protect against oxidized low-density lipoprotein-induced endothelial dysfunction by inhibiting the NF- κ B/NLRP3 pathway and improving cell-cell junctions. Chemico-biological interactions 2021; 345:109572.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34217687>
 7. Murtola TJ, Siltari A. Statins for Prostate Cancer: When and How Much? Clin Cancer Res 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34281913>
 8. Woo JS, Hong SJ, Cha DH *et al.* Comparison of the Efficacy and Safety of Atorvastatin 40 mg/ ω -3 fatty acids 4 g Fixed-Dose Combination and Atorvastatin 40 mg Monotherapy in Hypertriglyceridemic Patients Who Poorly Respond to Atorvastatin 40 mg Monotherapy: An 8-Week, Multicenter, Randomized, Double-Blind Phase III Study. Clinical therapeutics 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34332788>
 9. Hu J, Yang C, Yang G *et al.* Effects of atorvastatin doses on serum level of procalcitonin and predictors for major adverse cardiovascular events in patients with acute myocardial infarction: a pilot study and post hoc analysis. Coronary artery disease 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34292180>
 10. Khalighfard S, Khori V, Alizadeh AM *et al.* Dual effects of atorvastatin on angiogenesis pathways in the differentiation of mesenchymal stem cells. Eur J Pharmacol 2021; 907:174281. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34217710>
 11. Lv S, Yu H, Liu X, Gao X. The Study on the Mechanism of Huga Tablets in Treating Drug-Induced Liver Injury Induced by Atorvastatin. Frontiers in pharmacology 2021; 12:683707. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34262454>
 12. Nikalji R, Sen S. Rosuvastatin-Induced Rhabdomyolysis: A Case Report. Indian J Nephrol 2021; 31:190-193. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34267446>
 13. Saadat S, Boskabady MH. Anti-inflammatory and Antioxidant Effects of Rosuvastatin on Asthmatic, Hyperlipidemic, and Asthmatic-Hyperlipidemic Rat Models. Inflammation 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34226988>
 14. Lastuvkova H, Faradonbeh FA, Schreiberova J *et al.* Atorvastatin Modulates Bile Acid Homeostasis in Mice with Diet-Induced Nonalcoholic Steatohepatitis. Int J Mol Sci 2021; 22. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34208774>
 15. Shokrolahi F, Latif F, Shokrollahi P *et al.* Engineering atorvastatin loaded Mg-Mn/LDH nanoparticles and their composite with PLGA for bone tissue applications. Int J Pharm 2021; 606:120901.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34293469>
 16. Handayani W, Suharjo, Yogiarto M. Analysis of HMGB-1 level before and after providing atorvastatin standard therapy in coronary artery disease patients with type-2 diabetes mellitus compared to without type-2 diabetes mellitus. Journal of

- basic and clinical physiology and pharmacology 2021; 32:439-446.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34214372>
17. Laird J, Falk RH, Coyle M, Cuddy SAM. Rhabdomyolysis in the Setting of Concomitant Use of Tafamidis, Atorvastatin, and Amiodarone. JACC Case Rep 2020; 2:2372-2375. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34317174>
 18. Zvizdić F, Begić E, Dilić M *et al.* Effect of atorvastatin on systolic and diastolic function in patients with heart failure with reduced ejection fraction (HFrEF). Medicinski glasnik : official publication of the Medical Association of Zenica-Doboj Canton, Bosnia and Herzegovina 2021; 18.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34212706>
 19. Guan Y, Zhou P, Sun Z, Meng L. Simvastatin inhibites high glucose-induced renal tubular epithelial cells apoptosis by down-regulating miR-92a. Pak J Pharm Sci 2021; 34:411-415. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34275787>
 20. Shah PA, Zaidi HA, Syed HK *et al.* Formulation development and in vitro characterization of triple layer tablet containing amlodipine besylate, rosuvastatin calcium and hydrochlorothiazide. Pak J Pharm Sci 2021; 34:699-710.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34275805>
 21. Oprica M, Iota M, Daescu M *et al.* Spectroscopic studies on photodegradation of atorvastatin calcium. Scientific reports 2021; 11:15338.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34321518>
 22. Yamamuro S, Shinozaki T, Imuro S, Matsuyama Y. Mediation of atorvastatin's effect on cardiovascular disease via cholesterol lowering and anti-inflammatory actions in elderly type 2 diabetics. Stat Methods Med Res 2021;9622802211025988. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34187236>
 23. Li N, Guo XY, Zhou J *et al.* Atorvastatin Pretreatment Ameliorates Mesenchymal Stem Cell Migration through miR-146a/CXCR4 Signaling. Tissue engineering and regenerative medicine 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34260048>
 24. Sharma A, Sharma C, Raina S *et al.* A randomized open-label trial to evaluate the efficacy and safety of triple therapy with aspirin, atorvastatin, and nicorandil in hospitalised patients with SARS Cov-2 infection: A structured summary of a study protocol for a randomized controlled trial. Trials 2021; 22:451.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34266452>

Basic science

1. Sun J, Kumar Panda P, Kumar Samal S *et al.* Effects of Atorvastatin on T-Cell Activation and Apoptosis in Systemic Lupus Erythematosus and Novel Simulated Interactions With C-Reactive Protein and Interleukin 6. ACR open rheumatology 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34302321>
2. Peng WY, Huang AC, Ting CT, Tsai TH. Preclinical Pharmacokinetics and Pharmacodynamics of Coptidis Preparation in Combination with Lovastatin in High-Fat Diet-Induced Hyperlipidemic Rats. ACS omega 2021; 6:15804-15815.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34179624>
3. Zhang XB, Cheng HJ, Yuan YT *et al.* Atorvastatin attenuates intermittent hypoxia-induced myocardial oxidative stress in a mouse obstructive sleep apnea

- model. *Aging* 2021; 13:18870-18878.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34289453>
4. Zhang YX, Qu SS, Zhang LH *et al.* The Role of Ophiopogonin D in Atherosclerosis: Impact on Lipid Metabolism and Gut Microbiota. *The American journal of Chinese medicine* 2021; 49:1449-1471. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34263719>
 5. Abo-Zalam HB, El-Denshary ES, Abdelsalam RM *et al.* Therapeutic advancement of simvastatin-loaded solid lipid nanoparticles (SV-SLNs) in treatment of hyperlipidemia and attenuating hepatotoxicity, myopathy and apoptosis: Comprehensive study. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie* 2021; 139:111494.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34243595>
 6. Cheon YH, Lee CH, Kim S *et al.* Pitavastatin prevents ovariectomy-induced osteoporosis by regulating osteoclastic resorption and osteoblastic formation. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie* 2021; 139:111697.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34243614>
 7. Kudinov VA, Torkhovskaya TI, Zakharova TS *et al.* High-density lipoprotein remodeling by phospholipid nanoparticles improves cholesterol efflux capacity and protects from atherosclerosis. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie* 2021; 141:111900.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34328100>
 8. Malekpour Z, Akbari V, Varshosaz J, Taheri A. Preparation and characterization of poly (lactic-co-glycolic acid) nanofibers containing simvastatin coated with hyaluronic acid for using in periodontal tissue engineering. *Biotechnol Prog* 2021:e3195. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34296538>
 9. Tufail S, Siddique MI, Sarfraz M *et al.* Simvastatin nanoparticles loaded polymeric film as a potential strategy for diabetic wound healing: in vitro and in vivo evaluation. *Current drug delivery* 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34288836>
 10. Khalighfard S, Khorri V, Alizadeh AM *et al.* Dual effects of atorvastatin on angiogenesis pathways in the differentiation of mesenchymal stem cells. *Eur J Pharmacol* 2021; 907:174281. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34217710>
 11. Tomaszewski M, Zolkowska D, Plewa Z *et al.* Effect of acute and chronic exposure to lovastatin on the anticonvulsant action of classical antiepileptic drugs in the mouse maximal electroshock-induced seizure model. *Eur J Pharmacol* 2021; 907:174290. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34217711>
 12. Lv S, Yu H, Liu X, Gao X. The Study on the Mechanism of Huga Tablets in Treating Drug-Induced Liver Injury Induced by Atorvastatin. *Frontiers in pharmacology* 2021; 12:683707. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34262454>
 13. Li Z, Zhang J, Xue Y *et al.* Pitavastatin stimulates retinal angiogenesis via HMG-CoA reductase-independent activation of RhoA-mediated pathways and focal adhesion. *Graefes archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie* 2021; 259:2707-2716. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34328550>
 14. Saadat S, Boskabady MH. Anti-inflammatory and Antioxidant Effects of Rosuvastatin on Asthmatic, Hyperlipidemic, and Asthmatic-Hyperlipidemic Rat Models. *Inflammation* 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34226988>

15. Lastuvkova H, Faradonbeh FA, Schreiberova J *et al.* Atorvastatin Modulates Bile Acid Homeostasis in Mice with Diet-Induced Nonalcoholic Steatohepatitis. Int J Mol Sci 2021; 22. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34208774>
16. Wacinski P, Gadzinowski M, Dabrowski W *et al.* Anti-Inflammatory Effect of Very High Dose Local Vessel Wall Statin Administration: Poly(L,L-Lactide) Biodegradable Microspheres with Simvastatin for Drug Delivery System (DDS). Int J Mol Sci 2021; 22. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34299106>
17. Shokrolahi F, Latif F, Shokrollahi P *et al.* Engineering atorvastatin loaded Mg-Mn/LDH nanoparticles and their composite with PLGA for bone tissue applications. Int J Pharm 2021; 606:120901. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34293469>
18. Handayani W, Suharjono, Yogiarto M. Analysis of HMGB-1 level before and after providing atorvastatin standard therapy in coronary artery disease patients with type-2 diabetes mellitus compared to without type-2 diabetes mellitus. Journal of basic and clinical physiology and pharmacology 2021; 32:439-446. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34214372>
19. Guo G, Cai J. Rosuvastatin alleviated the liver ischemia reperfusion injury by activating the expression of peroxisome proliferator-activated receptor gamma (PPAR γ). J Bioenerg Biomembr 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34235609>
20. Sun T, Xing HL, Chen ZZ *et al.* Simvastatin reverses the harmful effects of high fat diet on titanium rod osseointegration in ovariectomized rats. J Bone Miner Metab 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34189660>
21. Soares DG, Bordini EAF, Bronze-Uhle ES *et al.* Chitosan-Calcium-Simvastatin Scaffold as an Inductive Cell-Free Platform. Journal of dental research 2021; 100:1118-1126. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34315311>
22. Nam GH, Kwon M, Jung H *et al.* Statin-mediated inhibition of RAS prenylation activates ER stress to enhance the immunogenicity of KRAS mutant cancer. J Immunother Cancer 2021; 9. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34330763>
23. Tenesaca S, Vasquez M, Alvarez M *et al.* Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors. J Immunother Cancer 2021; 9. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34321273>
24. Kagawa K, Imaizumi U, Fuchida S, Sanuki T. Effects of Atorvastatin on Sevoflurane Postconditioning in in vivo Rabbit Hearts. J Oral Biosci 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34280533>
25. Teo RD, Tieleman DP. Modulation of Phospholipid Bilayer Properties by Simvastatin. The journal of physical chemistry. B 2021; 125:8406-8418. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34296883>
26. Ressaissi A, Pacheco R, Serralheiro MLM. Molecular-level changes induced by hydroxycinnamic acid derivatives in HepG2 cell line: Comparison with pravastatin. Life sciences 2021; 283:119846. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34324915>
27. Jun JH, Oh KC, Park KH *et al.* Improvement of Osseointegration by Ultraviolet and/or Simvastatin Treatment on Titanium Implants with or without Bone Graft Materials. Materials (Basel, Switzerland) 2021; 14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34279277>

28. Moschetti A, Dagda RK, Ryan RO. Coenzyme Q nanodisks counteract the effect of statins on C2C12 myotubes. Nanomedicine : nanotechnology, biology, and medicine 2021; 37:102439. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256063>
29. Rakshit M, Darwitan A, Muktabar A *et al.* Anti-inflammatory potential of simvastatin loaded nanoliposomes in 2D and 3D foam cell models. Nanomedicine : nanotechnology, biology, and medicine 2021; 37:102434. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34214684>
30. Liang W, Shi J, Xia H, Wei X. A Novel Ruthenium-Fluvastatin Complex Downregulates SNCG Expression to Modulate Breast Carcinoma Cell Proliferation and Apoptosis via Activating the PI3K/Akt/mTOR/VEGF/MMP9 Pathway. Oxidative medicine and cellular longevity 2021; 2021:5537737. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34221232>
31. Guan Y, Zhou P, Sun Z, Meng L. Simvastatin inhibites high glucose-induced renal tubular epithelial cells apoptosis by down-regulating miR-92a. Pak J Pharm Sci 2021; 34:411-415. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34275787>
32. Meng M, Li X, Zhang X, Sun B. Baicalein inhibits the pharmacokinetics of simvastatin in rats via regulating the activity of CYP3A4. Pharmaceutical biology 2021; 59:880-883. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34214011>
33. Pescina S, Sonvico F, Clementino A *et al.* Preliminary Investigation on Simvastatin-Loaded Polymeric Micelles in View of the Treatment of the Back of the Eye. Pharmaceutics 2021; 13. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34207544>
34. Ossipov DA, Lüchow M, Malkoch M. Differentiating Co-Delivery of Bisphosphonate and Simvastatin by Self-Healing Hyaluronan Hydrogel Formed by Orthogonal "Clicks": An In-Vitro Assessment. Polymers (Basel) 2021; 13. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34206872>
35. Oprica M, Iota M, Daescu M *et al.* Spectroscopic studies on photodegradation of atorvastatin calcium. Scientific reports 2021; 11:15338. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34321518>
36. Li N, Guo XY, Zhou J *et al.* Atorvastatin Pretreatment Ameliorates Mesenchymal Stem Cell Migration through miR-146a/CXCR4 Signaling. Tissue engineering and regenerative medicine 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34260048>

Cancer

1. Moctezuma-Velazquez C, Abrales JG. Statins and Liver Cancer in Cirrhosis: The Most Relevant Questions Are Still Unanswered. Am J Gastroenterol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34279010>
2. Pinyopornpanish K, Al-Yaman W, Butler RS *et al.* Chemopreventive Effect of Statin on Hepatocellular Carcinoma in Patients With Nonalcoholic Steatohepatitis Cirrhosis. Am J Gastroenterol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34212895>
3. Duarte JA, de Barros ALB, Leite EA. The potential use of simvastatin for cancer treatment: A review. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2021; 141:111858. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34323700>

4. Brånvall E, Ekberg S, Eloranta S *et al.* Statin use and survival in 16 098 patients with non-Hodgkin lymphoma or chronic lymphocytic leukaemia treated in the rituximab era. British journal of haematology 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34331461>
5. Harewood R, Disney R, Kinross J *et al.* Medication use and risk of proximal colon cancer: a systematic review of prospective studies with narrative synthesis and meta-analysis. Cancer Causes Control 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34224060>
6. Saito K, Sato Y, Nakatani E *et al.* Statin exposure and pancreatic cancer incidence: A Japanese regional population-based cohort study, the Shizuoka Study. Cancer prevention research (Philadelphia, Pa.) 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34244151>
7. Murtola TJ, Siltari A. Statins for Prostate Cancer: When and How Much? Clin Cancer Res 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34281913>
8. Jiang W, Hu JW, He XR *et al.* Statins: a repurposed drug to fight cancer. Journal of experimental & clinical cancer research : CR 2021; 40:241. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34303383>
9. Nam GH, Kwon M, Jung H *et al.* Statin-mediated inhibition of RAS prenylation activates ER stress to enhance the immunogenicity of KRAS mutant cancer. J Immunother Cancer 2021; 9. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34330763>
10. Tenesaca S, Vasquez M, Alvarez M *et al.* Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors. J Immunother Cancer 2021; 9. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34321273>
11. Ceacareanu AC, Jolly SD, Nimako GK, Wintrob ZAP. Statin Type and Cancer Outcomes in Patients with Diabetes Type 2 and Solid Tumors. Journal of research in pharmacy practice 2021; 10:50-56. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34295853>
12. Choi WM, Kim HJ, Jo AJ *et al.* Association of aspirin and statin use with the risk of liver cancer in chronic hepatitis B: A nationwide population-based study. Liver international : official journal of the International Association for the Study of the Liver 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34242482>
13. Liang W, Shi J, Xia H, Wei X. A Novel Ruthenium-Fluvastatin Complex Downregulates SNCG Expression to Modulate Breast Carcinoma Cell Proliferation and Apoptosis via Activating the PI3K/Akt/mTOR/VEGF/MMP9 Pathway. Oxidative medicine and cellular longevity 2021; 2021:5537737. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34221232>
14. Huang CT, Liang YJ. Anti-tumor effect of statin on pancreatic adenocarcinoma: From concept to precision medicine. World journal of clinical cases 2021; 9:4500-4505. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34222418>
15. Xu Y, Xiao P, Ba TT *et al.* (Advances and controversies of statins application in prevention and treatment of hepatocellular carcinoma). Zhonghua zhong liu za zhi (Chinese journal of oncology) 2021; 43:751-755. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34289568>

Cost-effectiveness

1. Ademi Z, Ofori-Asenso R, Zomer E *et al.* The cost-effectiveness of icosapent ethyl in combination with statin therapy compared with statin alone for cardiovascular risk reduction. *Eur J Prev Cardiol* 2021; 28:897-904.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34298556>
2. Eisavi M, Mazaheri E, Rezapour A *et al.* The Cost-Effectiveness and Cost-Utility of Statin Drug for the Treatment of Patients with Cardiovascular Disease, A Systematic Review. *International journal of preventive medicine* 2021; 12:39.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34249288>

CVD

1. Masson W, Lobo M, Barbagelata L *et al.* Prognostic value of statin therapy in patients with myocardial infarction with nonobstructive coronary arteries (MINOCA): a meta-analysis. *Acta Cardiol* 2021:1-8.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34308792>
2. Park HW, Kim YG, Park GM *et al.* Cholesterol Control for Subclinical Coronary Atherosclerosis in Subjects Without Indication for Statin Therapy. *Am J Cardiol* 2021; 153:51-57. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34176598>
3. Baum SJ, Rane PB, Nunna S *et al.* Geographic variations in lipid-lowering therapy utilization, LDL-C levels, and proportion retrospectively meeting the ACC/AHA very high-risk criteria in a real-world population of patients with major atherosclerotic cardiovascular disease events in the United States. *Am J Prev Cardiol* 2021; 6:100177. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34327500>
4. Elder P, Sharma G, Gulati M, Michos ED. Identification of female-specific risk enhancers throughout the lifespan of women to improve cardiovascular disease prevention. *Am J Prev Cardiol* 2020; 2:100028.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34327455>
5. Fan W, Philip S, Toth PP *et al.* Estimated ASCVD risk according to statin use in US adults with borderline triglycerides: Results from National Health and Nutrition Examination Survey (NHANES) 2007-2014. *Am J Prev Cardiol* 2020; 3:100087.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34327466>
6. Khan SU, Michos ED. Cardiovascular mortality after intensive LDL-Cholesterol lowering: Does baseline LDL-Cholesterol really matter? *Am J Prev Cardiol* 2020; 1:100013. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34327454>
7. Okunrintemi V, Benson EA, Derbal O *et al.* Age-specific differences in patient reported outcomes among adults with atherosclerotic cardiovascular disease: Medical expenditure panel survey 2006-2015. *Am J Prev Cardiol* 2020; 3:100083.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34327463>
8. Toth PP. Low-Density Lipoprotein Cholesterol Treatment Rates in High Risk Patients: More Disappointment Despite Ever More Refined Evidence-Based Guidelines. *Am J Prev Cardiol* 2021; 6:100186.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34327506>

9. Vikulova DN, Skorniakov IS, Bitou B *et al.* Lipid-lowering therapy for primary prevention of premature atherosclerotic coronary artery disease: Eligibility, utilization, target achievement, and predictors of initiation. Am J Prev Cardiol 2020; 2:100036. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34327459>
10. Drexel H, Larcher B, Mader A *et al.* The LDL-C/ApoB ratio predicts major cardiovascular events in patients with established atherosclerotic cardiovascular disease. Atherosclerosis 2021; 329:44-49. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34183170>
11. Liu HH, Li S, Cao YX *et al.* Association of triglyceride-rich lipoprotein-cholesterol with recurrent cardiovascular events in statin-treated patients according to different inflammatory status. Atherosclerosis 2021; 330:29-35. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34225103>
12. Tunbridge MJ, Jardine AG. Atherosclerotic Vascular Disease Associated with Chronic Kidney Disease. Cardiol Clin 2021; 39:403-414. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34247753>
13. Hu J, Yang C, Yang G *et al.* Effects of atorvastatin doses on serum level of procalcitonin and predictors for major adverse cardiovascular events in patients with acute myocardial infarction: a pilot study and post hoc analysis. Coronary artery disease 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34292180>
14. Hayfron-Benjamin CF, Mosterd C, Maitland-van der Zee AH *et al.* Inflammation and its associations with aortic stiffness, coronary artery disease and peripheral artery disease in different ethnic groups: The HELIUS Study. EClinicalMedicine 2021; 38:101012. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34278285>
15. Pareek M, Mason RP, Bhatt DL. Icosapent ethyl: safely reducing cardiovascular risk in adults with elevated triglycerides. Expert opinion on drug safety 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253137>
16. Kawashima H, Serruys PW, Ono M *et al.* Impact of Optimal Medical Therapy on 10-Year Mortality After Coronary Revascularization. J Am Coll Cardiol 2021; 78:27-38. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34210411>
17. Formanowicz D, Krawczyk JB, Perek B *et al.* Management of High-Risk Atherosclerotic Patients by Statins May Be Supported by Logistic Model of Intima-Media Thickening. Journal of clinical medicine 2021; 10. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34209480>
18. Øvrehus KA, Diederichsen A, Grove EL *et al.* Reduction of Myocardial Infarction and All-Cause Mortality Associated to Statins in Patients Without Obstructive CAD. JACC. Cardiovascular imaging 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34274285>
19. Zvizdić F, Begić E, Dilić M *et al.* Effect of atorvastatin on systolic and diastolic function in patients with heart failure with reduced ejection fraction (HFrEF). Medicinski glasnik : official publication of the Medical Association of Zenica-Doboj Canton, Bosnia and Herzegovina 2021; 18. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34212706>
20. Gouda P, Savu A, Baaney KR *et al.* Long-term risk of death and recurrent cardiovascular events following acute coronary syndromes. PLoS One 2021; 16:e0254008. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34197547>
21. Zein A, Sulistiyana CS, Khasanah U *et al.* Statin and mortality in COVID-19: a systematic review and meta-analysis of pooled adjusted effect estimates from

- propensity-matched cohorts. Postgraduate medical journal 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34193549>
22. Huang K, Wen XQ, Ren N *et al*. Lipidomic profile in patients with a very high risk of atherosclerotic cardiovascular disease on PCSK9 inhibitor therapy. Rev Cardiovasc Med 2021; 22:461-467. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34258913>
23. Chidambaram V, Ruelas Castillo J, Kumar A *et al*. The association of atherosclerotic cardiovascular disease and statin use with inflammation and treatment outcomes in tuberculosis. Scientific reports 2021; 11:15283.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34315941>

Endothelium/inflammation

1. Sun J, Kumar Panda P, Kumar Samal S *et al*. Effects of Atorvastatin on T-Cell Activation and Apoptosis in Systemic Lupus Erythematosus and Novel Simulated Interactions With C-Reactive Protein and Interleukin 6. ACR open rheumatology 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34302321>
2. Mazhar J, Figtree G, Vernon ST *et al*. Progression of coronary atherosclerosis in patients without standard modifiable risk factors. Am J Prev Cardiol 2020; 4:100116. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34327476>
3. Nelson AJ, Puri R, Brennan DM *et al*. C-reactive protein levels and plaque regression with evolocumab: Insights from GLAGOV. Am J Prev Cardiol 2020; 3:100091. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34327467>
4. Santos Junior GGD, Araújo PSR, Leite KME *et al*. The Effect of Atorvastatin + Aspirin on the Endothelial Function Differs with Age in Patients with HIV: A Case-Control Study. Arquivos brasileiros de cardiologia 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34231792>
5. Abudalou M, Mohamed AS, Vega EA, Al Sbihi A. Colchicine-induced rhabdomyolysis: a review of 83 cases. BMJ case reports 2021; 14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34290008>
6. Hayfron-Benjamin CF, Mosterd C, Maitland-van der Zee AH *et al*. Inflammation and its associations with aortic stiffness, coronary artery disease and peripheral artery disease in different ethnic groups: The HELIUS Study. EClinicalMedicine 2021; 38:101012. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34278285>
7. Shabani M, Bakhshi H, Ostovaneh MR *et al*. Temporal change in inflammatory biomarkers and risk of cardiovascular events: the Multi-ethnic Study of Atherosclerosis. ESC heart failure 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34240828>
8. Young RP, Scott RJ. Statins as adjunct therapy in COPD: is it time to target innate immunity and cardiovascular risk? The European respiratory journal 2021; 58. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34326175>
9. Saadat S, Boskabady MH. Anti-inflammatory and Antioxidant Effects of Rosuvastatin on Asthmatic, Hyperlipidemic, and Asthmatic-Hyperlipidemic Rat Models. Inflammation 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34226988>
10. Rakshit M, Darwitan A, Muktabar A *et al*. Anti-inflammatory potential of simvastatin loaded nanoliposomes in 2D and 3D foam cell models. Nanomedicine :

nanotechnology, biology, and medicine 2021; 37:102434.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=34214684>

11. Chidambaram V, Ruelas Castillo J, Kumar A *et al*. The association of atherosclerotic cardiovascular disease and statin use with inflammation and treatment outcomes in tuberculosis. Scientific reports 2021; 11:15283.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34315941>
12. Yamamuro S, Shinozaki T, Imuro S, Matsuyama Y. Mediation g-formula for time-varying treatment and repeated-measured multiple mediators: Application to atorvastatin's effect on cardiovascular disease via cholesterol lowering and anti-inflammatory actions in elderly type 2 diabetics. Stat Methods Med Res 2021:9622802211025988. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34187236>

Ethnicity

1. Tung H, Lin HJ, Chen PL *et al*. Characterization of familial hypercholesterolemia in Taiwanese ischemic stroke patients. Aging 2021; 13:19339-19351.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34314377>
2. Park HW, Kim YG, Park GM *et al*. Cholesterol Control for Subclinical Coronary Atherosclerosis in Subjects Without Indication for Statin Therapy. Am J Cardiol 2021; 153:51-57. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34176598>
3. Patel J, Mehta A, Rifai MA *et al*. Hypertension guidelines and coronary artery calcification among South Asians: Results from MASALA and MESA. Am J Prev Cardiol 2021; 6:100158. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34327495>
4. Saito K, Sato Y, Nakatani E *et al*. Statin exposure and pancreatic cancer incidence: A Japanese regional population-based cohort study, the Shizuoka Study. Cancer prevention research (Philadelphia, Pa.) 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34244151>
5. Hadi A, AlAteeq MA. Level of Control of Dyslipidemia Among Patients Followed in Family Medicine Clinics in Riyadh, Saudi Arabia. Cureus 2021; 13:e15504.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34268035>
6. Hayfron-Benjamin CF, Mosterd C, Maitland-van der Zee AH *et al*. Inflammation and its associations with aortic stiffness, coronary artery disease and peripheral artery disease in different ethnic groups: The HELIUS Study. EClinicalMedicine 2021; 38:101012. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34278285>
7. Shin S, Wook Shin D, Young Cho I *et al*. Status of dyslipidemia management and statin undertreatment in Korean cancer survivors: A Korean National Health and Nutrition Examination Survey study. Eur J Prev Cardiol 2021; 28:864-872.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34298552>
8. Choi WM, Kim HJ, Jo AJ *et al*. Association of aspirin and statin use with the risk of liver cancer in chronic hepatitis B: A nationwide population-based study. Liver international : official journal of the International Association for the Study of the Liver 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34242482>
9. Eastwood SV, Mathur R, Sattar N *et al*. Ethnic differences in guideline-indicated statin initiation for people with type 2 diabetes in UK primary care, 2006-2019: A cohort study. PLoS Med 2021; 18:e1003672.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34185782>

10. Kwon OC, Park YB, Park MC. Effect of statins on the prevention of recurrent thrombosis in thrombotic antiphospholipid syndrome. Rheumatology (Oxford) 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34289012>
11. Chidambaram V, Ruelas Castillo J, Kumar A *et al.* The association of atherosclerotic cardiovascular disease and statin use with inflammation and treatment outcomes in tuberculosis. Scientific reports 2021; 11:15283. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34315941>
12. Jeong SM, Shin DW, Yoo TG *et al.* Association between statin use and Alzheimer's disease with dose response relationship. Scientific reports 2021; 11:15280. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34315986>

FH

1. Tung H, Lin HJ, Chen PL *et al.* Characterization of familial hypercholesterolemia in Taiwanese ischemic stroke patients. Aging 2021; 13:19339-19351. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34314377>
2. Cammisotto V, Baratta F, Castellani V *et al.* Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways. Int J Mol Sci 2021; 22. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34281247>
3. Langer A, Mancini GBJ, Tan M *et al.* Treatment Inertia in Patients With Familial Hypercholesterolemia. J Am Heart Assoc 2021; 10:e020126. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34238023>
4. Peterson AL, Bang M, Block RC *et al.* Cascade Screening and Treatment Initiation in Young Adults with Heterozygous Familial Hypercholesterolemia. Journal of clinical medicine 2021; 10. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34300259>
5. Gallo A, Pérez de Isla L, Charrière S *et al.* The Added Value of Coronary Calcium Score in Predicting Cardiovascular Events in Familial Hypercholesterolemia. JACC. Cardiovascular imaging 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34274263>

Genetics

1. Wang Y, Du X, Zhao R *et al.* Association of APOE polymorphisms with lipid-lowering efficacy of statins in atherosclerotic cardiovascular diseases. Ann Acad Med Singap 2021; 50:474-480. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34195754>
2. Carter AR, Gill D, Davey Smith G *et al.* Cross-sectional analysis of educational inequalities in primary prevention statin use in UK Biobank. Heart 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34315717>
3. Brunette CA, Vassy JL. The role of SLC01B1 genotyping in lowering cardiovascular risk. Pharmacogenomics 2021; 22:649-656. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34196599>

Guidelines

1. Pintarić H, Knezović Florijan M, Bridges I *et al.* Management of Hyperlipidemia in Very High and Extreme Risk Patients in Croatia: an observational study of treatment patterns and lipid control. *Acta clinica Croatica* 2020; 59:641-649. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34285435>
2. Cornelison P, Marrs JC, Anderson SL. Clinical Pharmacist Outreach to Increase Statin Use for Patients with Cardiovascular Disease in a Safety-Net Healthcare System. *American health & drug benefits* 2021; 14:63-69. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34267861>
3. Baum SJ, Rane PB, Nunna S *et al.* Geographic variations in lipid-lowering therapy utilization, LDL-C levels, and proportion retrospectively meeting the ACC/AHA very high-risk criteria in a real-world population of patients with major atherosclerotic cardiovascular disease events in the United States. *Am J Prev Cardiol* 2021; 6:100177. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34327500>
4. Fan W, Philip S, Toth PP *et al.* Estimated ASCVD risk according to statin use in US adults with borderline triglycerides: Results from National Health and Nutrition Examination Survey (NHANES) 2007-2014. *Am J Prev Cardiol* 2020; 3:100087. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34327466>
5. Feldman DI, Michos ED, Stone NJ *et al.* Same evidence, varying viewpoints: Three questions illustrating important differences between United States and European cholesterol guideline recommendations. *Am J Prev Cardiol* 2020; 4:100117. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34327477>
6. Gold ME, Nanna MG, Doerfler SM *et al.* Prevalence, treatment, and control of severe hyperlipidemia. *Am J Prev Cardiol* 2020; 3:100079. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34327462>
7. Jackson CL, Ahmad Z, Das SR, Khera A. The evaluation and management of patients with LDL-C \geq 190 mg/dL in a large health care system. *Am J Prev Cardiol* 2020; 1:100002. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34327446>
8. Khan SU, Michos ED. Cardiovascular mortality after intensive LDL-Cholesterol lowering: Does baseline LDL-Cholesterol really matter? *Am J Prev Cardiol* 2020; 1:100013. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34327454>
9. Klimchak AC, Patel MY, Iorga Ş R *et al.* Lipid treatment and goal attainment characteristics among persons with atherosclerotic cardiovascular disease in the United States. *Am J Prev Cardiol* 2020; 1:100010. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34327452>
10. Patel J, Mehta A, Rifai MA *et al.* Hypertension guidelines and coronary artery calcification among South Asians: Results from MASALA and MESA. *Am J Prev Cardiol* 2021; 6:100158. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34327495>
11. Toth PP. Low-Density Lipoprotein Cholesterol Treatment Rates in High Risk Patients: More Disappointment Despite Ever More Refined Evidence-Based Guidelines. *Am J Prev Cardiol* 2021; 6:100186. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34327506>
12. Vikulova DN, Skorniakov IS, Bitoiu B *et al.* Lipid-lowering therapy for primary prevention of premature atherosclerotic coronary artery disease: Eligibility, utilization, target achievement, and predictors of initiation. *Am J Prev Cardiol* 2020; 2:100036. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34327459>

13. Jaspers NEM, Visseren FLJ, van der Graaf Y *et al.* Communicating personalised statin therapy-effects as 10-year CVD-risk or CVD-free life-expectancy: does it improve decisional conflict? Three-armed, blinded, randomised controlled trial. BMJ Open 2021; 11:e041673.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34272216>
14. Morieri ML, Perrone V, Veronesi C *et al.* Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets' attainment in subjects with and without type 2 diabetes. Cardiovascular diabetology 2021; 20:144.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34271920>
15. Hasan S, Naugler C, Decker J *et al.* Laboratory reporting of framingham risk score increases statin prescriptions in at-risk patients. Clin Biochem 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34197811>
16. Deshotels MR, Virani SS, Ballantyne CM. Lipid Monitoring After Initiation of Lipid-Lowering Therapies: Return of Performance Measures? Current cardiology reports 2021; 23:116. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34269897>
17. Harris DE, Lacey A, Akbari A *et al.* Achievement of European guideline-recommended lipid levels post-percutaneous coronary intervention: A population-level observational cohort study. Eur J Prev Cardiol 2021; 28:854-861.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34298561>
18. Shin S, Wook Shin D, Young Cho I *et al.* Status of dyslipidemia management and statin undertreatment in Korean cancer survivors: A Korean National Health and Nutrition Examination Survey study. Eur J Prev Cardiol 2021; 28:864-872.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34298552>
19. Mueller MC, Usadel S, Kern WV *et al.* Proportion of patients eligible for statin therapy substantially varies between different cardiovascular disease risk calculators and guidelines used. Int J STD AIDS 2021:9564624211029392.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34233537>
20. Afifi T, Obeid M, Abdelati M *et al.* WHO/International Society of Hypertension risk prediction charts versus the UK Prospective Diabetes Study risk engine for cardiovascular risk assessment among patients with type 2 diabetes: a comparative study. Lancet 2021; 398 Suppl 1:S3.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34227962>
21. Eastwood SV, Mathur R, Sattar N *et al.* Ethnic differences in guideline-indicated statin initiation for people with type 2 diabetes in UK primary care, 2006-2019: A cohort study. PLoS Med 2021; 18:e1003672.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34185782>

LDL- related parameters

1. Pintarić H, Knezović Florijan M, Bridges I *et al.* Management of Hyperlipidemia in Very High and Extreme Risk Patients in Croatia: an observational study of treatment patterns and lipid control. Acta clinica Croatica 2020; 59:641-649.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34285435>
2. Baum SJ, Rane PB, Nunna S *et al.* Geographic variations in lipid-lowering therapy utilization, LDL-C levels, and proportion retrospectively meeting the ACC/AHA very high-risk criteria in a real-world population of patients with major atherosclerotic

- cardiovascular disease events in the United States. Am J Prev Cardiol 2021; 6:100177. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34327500>
3. Fan W, Philip S, Toth PP *et al.* Estimated ASCVD risk according to statin use in US adults with borderline triglycerides: Results from National Health and Nutrition Examination Survey (NHANES) 2007-2014. Am J Prev Cardiol 2020; 3:100087. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34327466>
 4. Gold ME, Nanna MG, Doerfler SM *et al.* Prevalence, treatment, and control of severe hyperlipidemia. Am J Prev Cardiol 2020; 3:100079. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34327462>
 5. Jackson CL, Ahmad Z, Das SR, Khera A. The evaluation and management of patients with LDL-C \geq 190 mg/dL in a large health care system. Am J Prev Cardiol 2020; 1:100002. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34327446>
 6. Khan SU, Michos ED. Cardiovascular mortality after intensive LDL-Cholesterol lowering: Does baseline LDL-Cholesterol really matter? Am J Prev Cardiol 2020; 1:100013. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34327454>
 7. Klimchak AC, Patel MY, Iorga S R *et al.* Lipid treatment and goal attainment characteristics among persons with atherosclerotic cardiovascular disease in the United States. Am J Prev Cardiol 2020; 1:100010. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34327452>
 8. Mazhar J, Figtree G, Vernon ST *et al.* Progression of coronary atherosclerosis in patients without standard modifiable risk factors. Am J Prev Cardiol 2020; 4:100116. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34327476>
 9. Toth PP. Low-Density Lipoprotein Cholesterol Treatment Rates in High Risk Patients: More Disappointment Despite Ever More Refined Evidence-Based Guidelines. Am J Prev Cardiol 2021; 6:100186. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34327506>
 10. Vikulova DN, Skorniakov IS, Bitoiu B *et al.* Lipid-lowering therapy for primary prevention of premature atherosclerotic coronary artery disease: Eligibility, utilization, target achievement, and predictors of initiation. Am J Prev Cardiol 2020; 2:100036. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34327459>
 11. Wang Y, Du X, Zhao R *et al.* Association of APOE polymorphisms with lipid-lowering efficacy of statins in atherosclerotic cardiovascular diseases. Ann Acad Med Singap 2021; 50:474-480. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34195754>
 12. Drexel H, Larcher B, Mader A *et al.* The LDL-C/ApoB ratio predicts major cardiovascular events in patients with established atherosclerotic cardiovascular disease. Atherosclerosis 2021; 329:44-49. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34183170>
 13. Mayo J, Hoffman T, Smith R, Kellicut D. Lipoprotein(a) as a unique primary risk factor for early atherosclerotic peripheral arterial disease. BMJ case reports 2021; 14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34193454>
 14. Jaspers NEM, Visseren FLJ, van der Graaf Y *et al.* Communicating personalised statin therapy-effects as 10-year CVD-risk or CVD-free life-expectancy: does it improve decisional conflict? Three-armed, blinded, randomised controlled trial. BMJ Open 2021; 11:e041673. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34272216>
 15. Morieri ML, Perrone V, Veronesi C *et al.* Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets' attainment in subjects with

- and without type 2 diabetes. Cardiovascular diabetology 2021; 20:144.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34271920>
16. Hasan S, Naugler C, Decker J *et al.* Laboratory reporting of framingham risk score increases statin prescriptions in at-risk patients. Clin Biochem 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34197811>
 17. Woo JS, Hong SJ, Cha DH *et al.* Comparison of the Efficacy and Safety of Atorvastatin 40 mg/ ω -3 fatty acids 4 g Fixed-Dose Combination and Atorvastatin 40 mg Monotherapy in Hypertriglyceridemic Patients Who Poorly Respond to Atorvastatin 40 mg Monotherapy: An 8-Week, Multicenter, Randomized, Double-Blind Phase III Study. Clinical therapeutics 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34332788>
 18. Hadi A, AlAteeq MA. Level of Control of Dyslipidemia Among Patients Followed in Family Medicine Clinics in Riyadh, Saudi Arabia. Cureus 2021; 13:e15504.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34268035>
 19. Rhainds D, Brodeur MR, Tardif JC. Lipoprotein (a): When to Measure and How to Treat? Curr Atheroscler Rep 2021; 23:51.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34235598>
 20. Deshotels MR, Virani SS, Ballantyne CM. Lipid Monitoring After Initiation of Lipid-Lowering Therapies: Return of Performance Measures? Current cardiology reports 2021; 23:116. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34269897>
 21. Harris DE, Lacey A, Akbari A *et al.* Achievement of European guideline-recommended lipid levels post-percutaneous coronary intervention: A population-level observational cohort study. Eur J Prev Cardiol 2021; 28:854-861.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34298561>
 22. Shin S, Wook Shin D, Young Cho I *et al.* Status of dyslipidemia management and statin undertreatment in Korean cancer survivors: A Korean National Health and Nutrition Examination Survey study. Eur J Prev Cardiol 2021; 28:864-872.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34298552>
 23. Dardano A, Daniele G, Penno G *et al.* Breaking Therapeutic Inertia With Alirocumab in an 80-Year-Old Patient With Severe Hypercholesterolemia: A Case Report. Frontiers in medicine 2021; 8:699477.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34307425>
 24. Fukase T, Dohi T, Kato Y *et al.* High Apolipoprotein E Levels Predict Adverse Limb Events in Patients with Peripheral Artery Disease Due to Peripheral Artery Disease Undergoing Endovascular Treatment and On-Statins Treatment. Int Heart J 2021; 62:872-878. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34276016>
 25. Kawashima H, Serruys PW, Ono M *et al.* Impact of Optimal Medical Therapy on 10-Year Mortality After Coronary Revascularization. J Am Coll Cardiol 2021; 78:27-38.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34210411>
 26. Schwartz GG, Szarek M, Bittner VA *et al.* Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. J Am Coll Cardiol 2021; 78:421-433. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34325831>
 27. Langer A, Mancini GBJ, Tan M *et al.* Treatment Inertia in Patients With Familial Hypercholesterolemia. J Am Heart Assoc 2021; 10:e020126.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34238023>

28. Fischer-Rasokat U, Renker M, Bänsch C *et al.* Effects of statins after transcatheter aortic valve implantation in key patient populations. Journal of cardiovascular pharmacology 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34321397>
29. Rogula S, Błażejowska E, Gąsecka A *et al.* Inclisiran-Silencing the Cholesterol, Speaking up the Prognosis. Journal of clinical medicine 2021; 10. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34199468>

Lifestyle

1. Carter AR, Gill D, Davey Smith G *et al.* Cross-sectional analysis of educational inequalities in primary prevention statin use in UK Biobank. Heart 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34315717>
2. Alvarez-Jimenez L, Moreno-Cabañas A, Ramirez-Jimenez M *et al.* Effectiveness of statins vs. exercise on reducing postprandial hypertriglyceridemia in dyslipidemic population: A systematic review and network meta-analysis. J Sport Health Sci 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34298253>
3. Watanabe LM, Navarro AM, Seale LA. Intersection between Obesity, Dietary Selenium, and Statin Therapy in Brazil. Nutrients 2021; 13. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34204631>

Meta-analyses

1. Masson W, Lobo M, Barbagelata L *et al.* Prognostic value of statin therapy in patients with myocardial infarction with nonobstructive coronary arteries (MINOCA): a meta-analysis. Acta Cardiol 2021;1-8. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34308792>
2. Nabizadeh F, Balabandian M, Sharafi AM *et al.* Statins and risk of amyotrophic lateral sclerosis: a systematic review and meta-analysis. Acta neurologica Belgica 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34322852>
3. Hou Q, Pang C, Chen Y. Association Between Vitamin D and Statin-Related Myopathy: A Meta-analysis. Am J Cardiovasc Drugs 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34296397>
4. Vahedian-Azimi A, Shojaie S, Banach M *et al.* Statin therapy in chronic viral hepatitis: a systematic review and meta-analysis of nine studies with 195,602 participants. Annals of medicine 2021; 53:1227-1242. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34296976>
5. Jia J, Zhang L, Wang L *et al.* A systematic review and meta-analysis on the efficacy of statins in the treatment of atherosclerosis. Ann Palliat Med 2021; 10:6793-6803. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34237978>
6. Harewood R, Disney R, Kinross J *et al.* Medication use and risk of proximal colon cancer: a systematic review of prospective studies with narrative synthesis and meta-analysis. Cancer Causes Control 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34224060>
7. Bohara S, Gaonkar VB, Garg K *et al.* Effect of statins on functional outcome and mortality following aneurysmal subarachnoid hemorrhage - Results of a meta-

- analysis, metaregression and trial sequential analysis. Clin Neurol Neurosurg 2021; 207:106787. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34225002>
8. Alvarez-Jimenez L, Moreno-Cabañas A, Ramirez-Jimenez M *et al.* Effectiveness of statins vs. exercise on reducing postprandial hypertriglyceridemia in dyslipidemic population: A systematic review and network meta-analysis. J Sport Health Sci 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34298253>
 9. Xiong X, Wu Z, Qin X *et al.* Statins reduce mortality after abdominal aortic aneurysm repair: A systematic review and meta-analysis. Journal of vascular surgery 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34197945>
 10. Sandwith L, Forget P. Statins in Healthy Adults: A Meta-Analysis. Medicina (Kaunas, Lithuania) 2021; 57. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34200448>
 11. Yetmar ZA, Chesdachai S, Kashour T *et al.* Prior Statin Use and Risk of Mortality and Severe Disease From Coronavirus Disease 2019: A Systematic Review and Meta-analysis. Open Forum Infect Dis 2021; 8:ofab284. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34258316>
 12. Zein A, Sulistiyana CS, Khasanah U *et al.* Statin and mortality in COVID-19: a systematic review and meta-analysis of pooled adjusted effect estimates from propensity-matched cohorts. Postgraduate medical journal 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34193549>

Metabolic Syndrome - Diabetes

1. Lohia P, Kapur S, Benjaram S *et al.* Statins and clinical outcomes in hospitalized COVID-19 patients with and without Diabetes Mellitus: a retrospective cohort study with propensity score matching. Cardiovascular diabetology 2021; 20:140. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34246277>
2. Morieri ML, Perrone V, Veronesi C *et al.* Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets' attainment in subjects with and without type 2 diabetes. Cardiovascular diabetology 2021; 20:144. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34271920>
3. Tufail S, Siddique MI, Sarfraz M *et al.* Simvastatin nanoparticles loaded polymeric film as a potential strategy for diabetic wound healing: in vitro and in vivo evaluation. Current drug delivery 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34288836>
4. Luchsinger JA, Younes N, Manly JJ *et al.* Association of Glycemia, Lipids, and Blood Pressure With Cognitive Performance in People With Type 2 Diabetes in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study. Diabetes Care 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34285097>
5. Hero C, Karlsson SA, Franzén S *et al.* Impact of Socioeconomic Factors and Gender on Refill Adherence and Persistence to Lipid-Lowering Therapy in Type 1 Diabetes. Diabetes Ther 2021; 12:2371-2386. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34292559>
6. Handayani W, Suharjono, Yogiarto M. Analysis of HMGB-1 level before and after providing atorvastatin standard therapy in coronary artery disease patients with type-2 diabetes mellitus compared to without type-2 diabetes mellitus. Journal of

- basic and clinical physiology and pharmacology 2021; 32:439-446.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34214372>
7. Ceacareanu AC, Jolly SD, Nimako GK, Wintrob ZAP. Statin Type and Cancer Outcomes in Patients with Diabetes Type 2 and Solid Tumors. Journal of research in pharmacy practice 2021; 10:50-56.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34295853>
 8. Afifi T, Obeid M, Abdelati M *et al.* WHO/International Society of Hypertension risk prediction charts versus the UK Prospective Diabetes Study risk engine for cardiovascular risk assessment among patients with type 2 diabetes: a comparative study. Lancet 2021; 398 Suppl 1:S3.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34227962>
 9. Guan Y, Zhou P, Sun Z, Meng L. Simvastatin inhibites high glucose-induced renal tubular epithelial cells apoptosis by down-regulating miR-92a. Pak J Pharm Sci 2021; 34:411-415. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34275787>
 10. Eastwood SV, Mathur R, Sattar N *et al.* Ethnic differences in guideline-indicated statin initiation for people with type 2 diabetes in UK primary care, 2006-2019: A cohort study. PLoS Med 2021; 18:e1003672.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34185782>

New Treatments

1. Nguyen NT, Nath PV, Mai VQ *et al.* Treatment of Severe Hypertriglyceridemia During Pregnancy With High Doses of Omega-3 Fatty Acid and Plasmapheresis. AACE Clin Case Rep 2021; 7:211-215. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34095491>
2. Wong ND, Bang M, Block RC *et al.* Perceptions and Barriers on the Use of Proprotein Subtilisin/Kexin Type 9 Inhibitors in Heterozygous Familial Hypercholesterolemia (From a Survey of Primary Care Physicians and Cardiologists). Am J Cardiol 2021; 152:57-62.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34147211>
3. Vuignier Y, Beaud F, Kosinski C *et al.* Exposure to alirocumab during the first trimester of pregnancy: A case report. Birth Defects Res 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34105316>
4. Smith W, Cheng-Lai A, Nawarskas J. Bempedoic Acid: A New Avenue for the Treatment of Dyslipidemia. Cardiology in review 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34132656>
5. Rached F, Santos RD. Beyond Statins and PCSK9 Inhibitors: Updates in Management of Familial and Refractory Hypercholesterolemias. Current cardiology reports 2021; 23:83. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34081216>
6. Kosmas CE, Muñoz Estrella A, Sourlas A, Pantou D. Inclisiran in dyslipidemia. Drugs of today (Barcelona, Spain : 1998) 2021; 57:311-319.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34061126>
7. Yagi R, Inoue K. Trends in Brand-name Statin Prescriptions Among Physicians Prescribing PCSK9 inhibitors in 2016-2018. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34126248>

8. George RT, Abuhatzira L, Stoughton SM *et al.* MEDI6012: Recombinant Human Lecithin Cholesterol Acyltransferase, High-Density Lipoprotein, and Low-Density Lipoprotein Receptor-Mediated Reverse Cholesterol Transport. J Am Heart Assoc 2021; 10:e014572. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34121413>
9. Fanous MM, Gianos E, Sperling LS *et al.* Early use of PCSK9 inhibitor therapy after heart transplantation from a hepatitis C virus positive donor. J Clin Lipidol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34120877>
10. McGraw-Senat CM, Dillard N, Guelda T *et al.* Bempedoic Acid: A First-in-Class Agent for Lowering Cholesterol Levels. The Senior care pharmacist 2021; 36:331-336. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34144722>
11. Sanz-Cuesta BE, Saver JL. Lipid-Lowering Therapy and Hemorrhagic Stroke Risk: Comparative Meta-Analysis of Statins and PCSK9 Inhibitors. Stroke 2021:Strokeaha121034576. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34154390>
12. Soška V, Kyselák O. Don't we forget about biological therapy of hypercholesterolemia with PCSK9-inhibitors? Vnitr Lek 2021; 67:138-142. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34171952>
13. Li YJ, Ma GS. (Clinical benefits and safety of low-level LDL-C in the new era of lipid-lowering). Zhonghua xin xue guan bing za zhi 2021; 49:548-553. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34126721>
14. Zhang H, Ye PC, Wang XM *et al.* (The relationship between genotype of familial hypercholesterolemia and the efficacy of PCSK9 inhibitors). Zhonghua xin xue guan bing za zhi 2021; 49:572-579. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34126724>

Other

1. Vahedian-Azimi A, Rahimibashar F, Najafi A *et al.* Association of In-hospital Use of Statins, Aspirin, and Renin-Angiotensin-Aldosterone Inhibitors with Mortality and ICU Admission Due to COVID-19. Advances in experimental medicine and biology 2021; 1327:205-214. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34279841>
2. Vahedian-Azimi A, Shojaie S, Banach M *et al.* Statin therapy in chronic viral hepatitis: a systematic review and meta-analysis of nine studies with 195,602 participants. Annals of medicine 2021; 53:1227-1242. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34296976>
3. Santos Junior GGD, Araújo PSR, Leite KME *et al.* The Effect of Atorvastatin + Aspirin on the Endothelial Function Differs with Age in Patients with HIV: A Case-Control Study. Arquivos brasileiros de cardiologia 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34231792>
4. Kollias A, Kyriakoulis KG, Kyriakoulis IG *et al.* Statin use and mortality in COVID-19 patients: Updated systematic review and meta-analysis. Atherosclerosis 2021; 330:114-121. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34243953>
5. Davoudi A, Ahmadi M, Sharifi A *et al.* Studying the Effect of Taking Statins before Infection in the Severity Reduction of COVID-19 with Machine Learning. BioMed research international 2021; 2021:9995073. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250095>

6. Lohia P, Kapur S, Benjaram S *et al.* Statins and clinical outcomes in hospitalized COVID-19 patients with and without Diabetes Mellitus: a retrospective cohort study with propensity score matching. Cardiovascular diabetology 2021; 20:140. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34246277>
7. Kumar V, Liu H, Wu C. Drug repurposing against SARS-CoV-2 receptor binding domain using ensemble-based virtual screening and molecular dynamics simulations. Comput Biol Med 2021; 135:104634. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256255>
8. Jain V, Al Rifai M, Mahtta D *et al.* Highlights from Studies Presented at the Virtual American College of Cardiology Scientific Sessions 2021: Staying Updated with the Latest Advancements in Prevention. Curr Atheroscler Rep 2021; 23:50. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34226979>
9. Chatterjee S, Vardhan B, Singh DK *et al.* Should statins be considered for the management of mucormycosis in COVID-19? Diabetes & metabolic syndrome 2021; 15:102162. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34186353>
10. Israel A, Schäffer AA, Cicurel A *et al.* Identification of drugs associated with reduced severity of COVID-19 - a case-control study in a large population. eLife 2021; 10. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34313216>
11. Thompson W, Jarbøl D, Nielsen JB *et al.* GP preferences for discussing statin deprescribing: a discrete choice experiment. Family practice 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268565>
12. Yayan J, Bald M, Franke KJ. No Independent Influence of Statins on the Chronic Obstructive Pulmonary Disease Exacerbation Rate: A Cohort Observation Study Over 10 Years. International journal of general medicine 2021; 14:2883-2892. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34234518>
13. Mueller MC, Usadel S, Kern WV *et al.* Proportion of patients eligible for statin therapy substantially varies between different cardiovascular disease risk calculators and guidelines used. Int J STD AIDS 2021:9564624211029392. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34233537>
14. Sutton SS, Magagnoli JC, Cummings TH, Hardin JW. Statin Exposure and Risk of Prosthetic Joint Infection After Total Knee or Hip Arthroplasty Among U.S. Veterans. The Journal of arthroplasty 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34229942>
15. Choi J, Kim H, Jun J *et al.* Recurrent Pancreatitis in a Pregnant Woman with Severe Hypertriglyceridemia Successfully Managed by Multiple Plasmapheresis. J Atheroscler Thromb 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34219115>
16. Morgan DJ, Pineles L, Owczarzak J *et al.* Clinician Conceptualization of the Benefits of Treatments for Individual Patients. JAMA network open 2021; 4:e2119747. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34287630>
17. Nardolillo JA, Marrs JC, Anderson SL *et al.* Retrospective cohort study of statin prescribing for primary prevention among people living with HIV. JRSM cardiovascular disease 2021; 10:20480040211031068. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34290861>
18. Olszewska-Parasiewicz J, Szarpak Ł, Rogula S *et al.* Statins in COVID-19 Therapy. Life (Basel) 2021; 11. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34208435>

19. Pyarali F, Iordanov R, Ebner B *et al.* Cardiovascular disease and prevention among people living with HIV in South Florida. Medicine (Baltimore) 2021; 100:e26631. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34260554>
20. Bertero E, Heusch G, Münzel T, Maack C. A pathophysiological compass to personalize antianginal drug treatment. Nat Rev Cardiol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34234310>
21. Yetmar ZA, Chesdachai S, Kashour T *et al.* Prior Statin Use and Risk of Mortality and Severe Disease From Coronavirus Disease 2019: A Systematic Review and Meta-analysis. Open Forum Infect Dis 2021; 8:ofab284. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34258316>
22. Daniels LB, Ren J, Kumar K *et al.* Relation of prior statin and anti-hypertensive use to severity of disease among patients hospitalized with COVID-19: Findings from the American Heart Association's COVID-19 Cardiovascular Disease Registry. PLoS One 2021; 16:e0254635. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34264974>
23. Zein A, Sulistiyana CS, Khasanah U *et al.* Statin and mortality in COVID-19: a systematic review and meta-analysis of pooled adjusted effect estimates from propensity-matched cohorts. Postgraduate medical journal 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34193549>
24. Mysore Y, Del Amo EM, Loukovaara S *et al.* Author Correction: Statins for the prevention of proliferative vitreoretinopathy: cellular responses in cultured cells and clinical statin concentrations in the vitreous. Scientific reports 2021; 11:15327. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34294746>
25. Sharma A, Sharma C, Raina S *et al.* A randomized open-label trial to evaluate the efficacy and safety of triple therapy with aspirin, atorvastatin, and nicorandil in hospitalised patients with SARS Cov-2 infection: A structured summary of a study protocol for a randomized controlled trial. Trials 2021; 22:451. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34266452>

PAD and statins

1. Mayo J, Hoffman T, Smith R, Kellicut D. Lipoprotein(a) as a unique primary risk factor for early atherosclerotic peripheral arterial disease. BMJ case reports 2021; 14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34193454>
2. Hayfron-Benjamin CF, Mosterd C, Maitland-van der Zee AH *et al.* Inflammation and its associations with aortic stiffness, coronary artery disease and peripheral artery disease in different ethnic groups: The HELIUS Study. EClinicalMedicine 2021; 38:101012. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34278285>
3. Fukase T, Dohi T, Kato Y *et al.* High Apolipoprotein E Levels Predict Adverse Limb Events in Patients with Peripheral Artery Disease Due to Peripheral Artery Disease Undergoing Endovascular Treatment and On-Statins Treatment. Int Heart J 2021; 62:872-878. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34276016>
4. Allar BG, Swerdlow NJ, de Guerre L *et al.* Preoperative statin therapy is associated with higher 5-year survival after thoracic endovascular aortic repair. Journal of vascular surgery 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34182025>

5. Xiong X, Wu Z, Qin X *et al.* Statins reduce mortality after abdominal aortic aneurysm repair: A systematic review and meta-analysis. Journal of vascular surgery 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34197945>

Pleiotropic effects of statins

1. Sun J, Kumar Panda P, Kumar Samal S *et al.* Effects of Atorvastatin on T-Cell Activation and Apoptosis in Systemic Lupus Erythematosus and Novel Simulated Interactions With C-Reactive Protein and Interleukin 6. ACR open rheumatology 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34302321>
2. Zhang XB, Cheng HJ, Yuan YT *et al.* Atorvastatin attenuates intermittent hypoxia-induced myocardial oxidative stress in a mouse obstructive sleep apnea model. Aging 2021; 13:18870-18878. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34289453>
3. Pinyopornpanish K, Al-Yaman W, Butler RS *et al.* Chemopreventive Effect of Statin on Hepatocellular Carcinoma in Patients With Nonalcoholic Steatohepatitis Cirrhosis. Am J Gastroenterol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34212895>
4. Vikulova DN, Skorniakov IS, Bitoiu B *et al.* Lipid-lowering therapy for primary prevention of premature atherosclerotic coronary artery disease: Eligibility, utilization, target achievement, and predictors of initiation. Am J Prev Cardiol 2020; 2:100036. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34327459>
5. Vahedian-Azimi A, Shojaie S, Banach M *et al.* Statin therapy in chronic viral hepatitis: a systematic review and meta-analysis of nine studies with 195,602 participants. Annals of medicine 2021; 53:1227-1242. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34296976>
6. Thiermeier N, Lämmer R, Mardin C, Hohberger B. Erlanger Glaucoma Registry: Effect of a Long-Term Therapy with Statins and Acetyl Salicylic Acid on Glaucoma Conversion and Progression. Biology (Basel) 2021; 10. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34208432>
7. Cheon YH, Lee CH, Kim S *et al.* Pitavastatin prevents ovariectomy-induced osteoporosis by regulating osteoclastic resorption and osteoblastic formation. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2021; 139:111697. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34243614>
8. Duarte JA, de Barros ALB, Leite EA. The potential use of simvastatin for cancer treatment: A review. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2021; 141:111858. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34323700>
9. Malekpour Z, Akbari V, Varshosaz J, Taheri A. Preparation and characterization of poly (lactic-co-glycolic acid) nanofibers containing simvastatin coated with hyaluronic acid for using in periodontal tissue engineering. Biotechnol Prog 2021:e3195. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34296538>
10. Brånvall E, Ekberg S, Eloranta S *et al.* Statin use and survival in 16 098 patients with non-Hodgkin lymphoma or chronic lymphocytic leukaemia treated in the rituximab

- era. British journal of haematology 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34331461>
11. Saito K, Sato Y, Nakatani E *et al.* Statin exposure and pancreatic cancer incidence: A Japanese regional population-based cohort study, the Shizuoka Study. Cancer prevention research (Philadelphia, Pa.) 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34244151>
 12. Zapatero-Belinchón FJ, Ötjengerdes R, Sheldon J *et al.* Interdependent Impact of Lipoprotein Receptors and Lipid-Lowering Drugs on HCV Infectivity. Cells 2021; 10. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34209751>
 13. Sivasinprasasn S, Wikan N, Tocharus J *et al.* Pelargonic acid vanillylamide and rosuvastatin protect against oxidized low-density lipoprotein-induced endothelial dysfunction by inhibiting the NF- κ B/NLRP3 pathway and improving cell-cell junctions. Chemico-biological interactions 2021; 345:109572. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34217687>
 14. Erkol A, Dalgıç Y, Yıldırım S, Turan B. Incidence and predictors of prolonged hemodynamic depression after carotid artery stenting: Yet another benefit of statins? Clin Neurol Neurosurg 2021; 207:106786. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34198224>
 15. Tufail S, Siddique MI, Sarfraz M *et al.* Simvastatin nanoparticles loaded polymeric film as a potential strategy for diabetic wound healing: in vitro and in vivo evaluation. Current drug delivery 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34288836>
 16. Al Salman M, Ghiasi M, Farid AS *et al.* Oral simvastatin combined with narrowband UVB for the treatment of psoriasis: A randomized controlled trial. Dermatologic therapy 2021:e15075. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34327798>
 17. Chatterjee S, Vardhan B, Singh DK *et al.* Should statins be considered for the management of mucormycosis in COVID-19? Diabetes & metabolic syndrome 2021; 15:102162. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34186353>
 18. Israel A, Schäffer AA, Cicurel A *et al.* Identification of drugs associated with reduced severity of COVID-19 - a case-control study in a large population. eLife 2021; 10. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34313216>
 19. Khalighfard S, Khori V, Alizadeh AM *et al.* Dual effects of atorvastatin on angiogenesis pathways in the differentiation of mesenchymal stem cells. Eur J Pharmacol 2021; 907:174281. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34217710>
 20. Tomaszewski M, Zolkowska D, Plewa Z *et al.* Effect of acute and chronic exposure to lovastatin on the anticonvulsant action of classical antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Eur J Pharmacol 2021; 907:174290. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34217711>
 21. Young RP, Scott RJ. Statins as adjunct therapy in COPD: is it time to target innate immunity and cardiovascular risk? The European respiratory journal 2021; 58. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34326175>
 22. Saadat S, Boskabady MH. Anti-inflammatory and Antioxidant Effects of Rosuvastatin on Asthmatic, Hyperlipidemic, and Asthmatic-Hyperlipidemic Rat Models. Inflammation 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34226988>
 23. Cammisotto V, Baratta F, Castellani V *et al.* Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways. Int J Mol Sci 2021; 22. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34281247>

24. Lastuvkova H, Faradonbeh FA, Schreiberova J *et al.* Atorvastatin Modulates Bile Acid Homeostasis in Mice with Diet-Induced Nonalcoholic Steatohepatitis. Int J Mol Sci 2021; 22. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34208774>
25. Wacinski P, Gadzinowski M, Dabrowski W *et al.* Anti-Inflammatory Effect of Very High Dose Local Vessel Wall Statin Administration: Poly(L,L-Lactide) Biodegradable Microspheres with Simvastatin for Drug Delivery System (DDS). Int J Mol Sci 2021; 22. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34299106>
26. Shokrolahi F, Latif F, Shokrollahi P *et al.* Engineering atorvastatin loaded Mg-Mn/LDH nanoparticles and their composite with PLGA for bone tissue applications. Int J Pharm 2021; 606:120901. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34293469>
27. Lee MC, Peng TR, Chen BL *et al.* Effects of various statins on depressive symptoms: A network meta-analysis. Journal of affective disorders 2021; 293:205-213. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34217957>
28. Sutton SS, Magagnoli JC, Cummings TH, Hardin JW. Statin Exposure and Risk of Prosthetic Joint Infection After Total Knee or Hip Arthroplasty Among U.S. Veterans. The Journal of arthroplasty 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34229942>
29. Guo G, Cai J. Rosuvastatin alleviated the liver ischemia reperfusion injury by activating the expression of peroxisome proliferator-activated receptor gamma (PPAR γ). J Bioenerg Biomembr 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34235609>
30. Sun T, Xing HL, Chen ZZ *et al.* Simvastatin reverses the harmful effects of high fat diet on titanium rod osseointegration in ovariectomized rats. J Bone Miner Metab 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34189660>
31. Jiang W, Hu JW, He XR *et al.* Statins: a repurposed drug to fight cancer. Journal of experimental & clinical cancer research : CR 2021; 40:241. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34303383>
32. Zeki Al Hazzouri A, Jawadekar N, Grasset L *et al.* Statins and cognitive decline in the Cardiovascular Health Study: A comparison of different analytical approaches. J Gerontol A Biol Sci Med Sci 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34331536>
33. Nam GH, Kwon M, Jung H *et al.* Statin-mediated inhibition of RAS prenylation activates ER stress to enhance the immunogenicity of KRAS mutant cancer. J Immunother Cancer 2021; 9. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34330763>
34. Tenesaca S, Vasquez M, Alvarez M *et al.* Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors. J Immunother Cancer 2021; 9. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34321273>
35. Kagawa K, Imaizumi U, Fuchida S, Sanuki T. Effects of Atorvastatin on Sevoflurane Postconditioning in in vivo Rabbit Hearts. J Oral Biosci 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34280533>
36. Palermo G, Giannoni S, Giuntini M *et al.* Statins in Parkinson's Disease: Influence on Motor Progression. Journal of Parkinson's disease 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34275907>

37. Teo RD, Tieleman DP. Modulation of Phospholipid Bilayer Properties by Simvastatin. The journal of physical chemistry. B 2021; 125:8406-8418.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34296883>
38. Ceacareanu AC, Jolly SD, Nimako GK, Wintrob ZAP. Statin Type and Cancer Outcomes in Patients with Diabetes Type 2 and Solid Tumors. Journal of research in pharmacy practice 2021; 10:50-56.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34295853>
39. Lin M, Xu T, Zhang W *et al.* Effect of statins on post-contrast acute kidney injury: a multicenter retrospective observational study. Lipids Health Dis 2021; 20:63.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34225750>
40. Choi WM, Kim HJ, Jo AJ *et al.* Association of aspirin and statin use with the risk of liver cancer in chronic hepatitis B: A nationwide population-based study. Liver international : official journal of the International Association for the Study of the Liver 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34242482>
41. Zvizdić F, Begić E, Dilić M *et al.* Effect of atorvastatin on systolic and diastolic function in patients with heart failure with reduced ejection fraction (HFrEF). Medicinski glasnik : official publication of the Medical Association of Zenica-Doboj Canton, Bosnia and Herzegovina 2021; 18.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34212706>
42. Rimpelová S, Kolář M, Strnad H *et al.* Comparison of Transcriptomic Profiles of MiaPaCa-2 Pancreatic Cancer Cells Treated with Different Statins. Molecules (Basel, Switzerland) 2021; 26. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34207840>
43. Rakshit M, Darwitan A, Muktabar A *et al.* Anti-inflammatory potential of simvastatin loaded nanoliposomes in 2D and 3D foam cell models. Nanomedicine : nanotechnology, biology, and medicine 2021; 37:102434.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34214684>
44. Liang W, Shi J, Xia H, Wei X. A Novel Ruthenium-Fluvastatin Complex Downregulates SNCG Expression to Modulate Breast Carcinoma Cell Proliferation and Apoptosis via Activating the PI3K/Akt/mTOR/VEGF/MMP9 Pathway. Oxidative medicine and cellular longevity 2021; 2021:5537737.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34221232>
45. Ossipov DA, Lüchow M, Malkoch M. Differentiating Co-Delivery of Bisphosphonate and Simvastatin by Self-Healing Hyaluronan Hydrogel Formed by Orthogonal "Clicks": An In-Vitro Assessment. Polymers (Basel) 2021; 13.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34206872>
46. Kwon OC, Park YB, Park MC. Effect of statins on the prevention of recurrent thrombosis in thrombotic antiphospholipid syndrome. Rheumatology (Oxford) 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34289012>
47. Chidambaram V, Ruelas Castillo J, Kumar A *et al.* The association of atherosclerotic cardiovascular disease and statin use with inflammation and treatment outcomes in tuberculosis. Scientific reports 2021; 11:15283.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34315941>
48. Jeong SM, Shin DW, Yoo TG *et al.* Association between statin use and Alzheimer's disease with dose response relationship. Scientific reports 2021; 11:15280.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34315986>

49. Kim SY, Lee CH, Min C *et al.* Association between statin medication and hearing impairment in a national health screening cohort. Scientific reports 2021; 11:14388. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34257355>
50. Yamamuro S, Shinozaki T, Imuro S, Matsuyama Y. Mediation g-formula for time-varying treatment and repeated-measured multiple mediators: Application to atorvastatin's effect on cardiovascular disease via cholesterol lowering and anti-inflammatory actions in elderly type 2 diabetics. Stat Methods Med Res 2021:9622802211025988. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34187236>
51. Bordbar M, de Mutsert R, Cevval M *et al.* Differential effect of statin use on coagulation markers: an active comparative analysis in the NEO study. Thromb J 2021; 19:45. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34176487>
52. Huang CT, Liang YJ. Anti-tumor effect of statin on pancreatic adenocarcinoma: From concept to precision medicine. World journal of clinical cases 2021; 9:4500-4505. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34222418>
53. Xu Y, Xiao P, Ba TT *et al.* (Advances and controversies of statins application in prevention and treatment of hepatocellular carcinoma). Zhonghua zhong liu za zhi (Chinese journal of oncology) 2021; 43:751-755. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34289568>

Primary Prevention

1. Cai T, Abel L, Langford O *et al.* Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses. Bmj 2021; 374:n1537. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34261627>
2. Sandwith L, Forget P. Statins in Healthy Adults: A Meta-Analysis. Medicina (Kaunas, Lithuania) 2021; 57. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34200448>
3. Kim SY, Lee CH, Min C *et al.* Association between statin medication and hearing impairment in a national health screening cohort. Scientific reports 2021; 11:14388. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34257355>
4. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34126723>

Registry data

1. Park HW, Kim YG, Park GM *et al.* Cholesterol Control for Subclinical Coronary Atherosclerosis in Subjects Without Indication for Statin Therapy. Am J Cardiol 2021; 153:51-57. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34176598>
2. Pinyopornpanish K, Al-Yaman W, Butler RS *et al.* Chemopreventive Effect of Statin on Hepatocellular Carcinoma in Patients With Nonalcoholic Steatohepatitis Cirrhosis. Am J Gastroenterol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34212895>
3. Fan W, Philip S, Toth PP *et al.* Estimated ASCVD risk according to statin use in US adults with borderline triglycerides: Results from National Health and Nutrition Examination Survey (NHANES) 2007-2014. Am J Prev Cardiol 2020; 3:100087. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34327466>

4. Jackson CL, Ahmad Z, Das SR, Khera A. The evaluation and management of patients with LDL-C \geq 190 mg/dL in a large health care system. Am J Prev Cardiol 2020; 1:100002. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34327446>
5. Thiermeier N, Lämmer R, Mardin C, Hohberger B. Erlanger Glaucoma Registry: Effect of a Long-Term Therapy with Statins and Acetyl Salicylic Acid on Glaucoma Conversion and Progression. Biology (Basel) 2021; 10. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34208432>
6. Brånvall E, Ekberg S, Eloranta S *et al.* Statin use and survival in 16 098 patients with non-Hodgkin lymphoma or chronic lymphocytic leukaemia treated in the rituximab era. British journal of haematology 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34331461>
7. Saito K, Sato Y, Nakatani E *et al.* Statin exposure and pancreatic cancer incidence: A Japanese regional population-based cohort study, the Shizuoka Study. Cancer prevention research (Philadelphia, Pa.) 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34244151>
8. Lohia P, Kapur S, Benjaram S *et al.* Statins and clinical outcomes in hospitalized COVID-19 patients with and without Diabetes Mellitus: a retrospective cohort study with propensity score matching. Cardiovascular diabetology 2021; 20:140. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34246277>
9. Skajaa N, Bakos I, Horváth-Puhó E *et al.* Statin Initiation and Risk of Amyotrophic Lateral Sclerosis: A Danish Population-based Cohort Study. Epidemiology 2021; 32:756-762. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34183532>
10. Shabani M, Bakhshi H, Ostovaneh MR *et al.* Temporal change in inflammatory biomarkers and risk of cardiovascular events: the Multi-ethnic Study of Atherosclerosis. ESC heart failure 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34240828>
11. Harris DE, Lacey A, Akbari A *et al.* Achievement of European guideline-recommended lipid levels post-percutaneous coronary intervention: A population-level observational cohort study. Eur J Prev Cardiol 2021; 28:854-861. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34298561>
12. Shin S, Wook Shin D, Young Cho I *et al.* Status of dyslipidemia management and statin undertreatment in Korean cancer survivors: A Korean National Health and Nutrition Examination Survey study. Eur J Prev Cardiol 2021; 28:864-872. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34298552>
13. Carter AR, Gill D, Davey Smith G *et al.* Cross-sectional analysis of educational inequalities in primary prevention statin use in UK Biobank. Heart 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34315717>
14. Yayan J, Bald M, Franke KJ. No Independent Influence of Statins on the Chronic Obstructive Pulmonary Disease Exacerbation Rate: A Cohort Observation Study Over 10 Years. International journal of general medicine 2021; 14:2883-2892. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34234518>
15. Fischer-Rasokat U, Renker M, Bänsch C *et al.* Effects of statins after transcatheter aortic valve implantation in key patient populations. Journal of cardiovascular pharmacology 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34321397>
16. Wańkowicz P, Staszewski J, Dębiec A *et al.* Pre-Stroke Statin Therapy Improves In-Hospital Prognosis Following Acute Ischemic Stroke Associated with Well-

- Controlled Nonvalvular Atrial Fibrillation. Journal of clinical medicine 2021; 10. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34300202>
17. Zeki Al Hazzouri A, Jawadekar N, Grasset L *et al.* Statins and cognitive decline in the Cardiovascular Health Study: A comparison of different analytical approaches. J Gerontol A Biol Sci Med Sci 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34331536>
 18. Øvrehus KA, Diederichsen A, Grove EL *et al.* Reduction of Myocardial Infarction and All-Cause Mortality Associated to Statins in Patients Without Obstructive CAD. JACC. Cardiovascular imaging 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34274285>
 19. Choi WM, Kim HJ, Jo AJ *et al.* Association of aspirin and statin use with the risk of liver cancer in chronic hepatitis B: A nationwide population-based study. Liver international : official journal of the International Association for the Study of the Liver 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34242482>
 20. Daniels LB, Ren J, Kumar K *et al.* Relation of prior statin and anti-hypertensive use to severity of disease among patients hospitalized with COVID-19: Findings from the American Heart Association's COVID-19 Cardiovascular Disease Registry. PLoS One 2021; 16:e0254635. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34264974>
 21. Gouda P, Savu A, Baaney KR *et al.* Long-term risk of death and recurrent cardiovascular events following acute coronary syndromes. PLoS One 2021; 16:e0254008. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34197547>
 22. Chidambaram V, Ruelas Castillo J, Kumar A *et al.* The association of atherosclerotic cardiovascular disease and statin use with inflammation and treatment outcomes in tuberculosis. Scientific reports 2021; 11:15283. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34315941>
 23. Jeong SM, Shin DW, Yoo TG *et al.* Association between statin use and Alzheimer's disease with dose response relationship. Scientific reports 2021; 11:15280. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34315986>

Renal Disease

1. Wu H, Sharaf M, Shalansky K, Zalunardo N. Evaluation of Statin Use and Prescribing in Patients with Chronic Kidney Disease Not Receiving Treatment with Kidney Transplant or Dialysis. The Canadian journal of hospital pharmacy 2021; 74:219-226. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248162>
2. Thobani A, Jacobson TA. Dyslipidemia in Patients with Kidney Disease. Cardiol Clin 2021; 39:353-363. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34247749>
3. Tunbridge MJ, Jardine AG. Atherosclerotic Vascular Disease Associated with Chronic Kidney Disease. Cardiol Clin 2021; 39:403-414. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34247753>
4. Yu AS, Liang B, Yang ST *et al.* Statin use and survival among ESKD patients hospitalized with sepsis. Clinical kidney journal 2021; 14:1710-1712. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34276978>
5. Genser B, Wanner C, März W. A scoring system for predicting individual treatment effects of statins in type 2 diabetes patients on haemodialysis. Eur J Prev Cardiol 2021; 28:838-851. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34298559>

6. Lin M, Xu T, Zhang W *et al.* Effect of statins on post-contrast acute kidney injury: a multicenter retrospective observational study. Lipids Health Dis 2021; 20:63. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34225750>
7. Guan Y, Zhou P, Sun Z, Meng L. Simvastatin inhibites high glucose-induced renal tubular epithelial cells apoptosis by down-regulating miR-92a. Pak J Pharm Sci 2021; 34:411-415. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34275787>

Reviews

1. Moctezuma-Velazquez C, Abrales JG. Statins and Liver Cancer in Cirrhosis: The Most Relevant Questions Are Still Unanswered. Am J Gastroenterol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34279010>
2. Feldman DI, Michos ED, Stone NJ *et al.* Same evidence, varying viewpoints: Three questions illustrating important differences between United States and European cholesterol guideline recommendations. Am J Prev Cardiol 2020; 4:100117. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34327477>
3. Božina N, Ganoci L, Simičević L *et al.* Drug-drug-gene interactions as mediators of adverse drug reactions to diclofenac and statins: a case report and literature review. Arhiv za higijenu rada i toksikologiju 2021; 72:114-128. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34187111>
4. Duarte JA, de Barros ALB, Leite EA. The potential use of simvastatin for cancer treatment: A review. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2021; 141:111858. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34323700>
5. Cai T, Abel L, Langford O *et al.* Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses. Bmj 2021; 374:n1537. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34261627>
6. Thobani A, Jacobson TA. Dyslipidemia in Patients with Kidney Disease. Cardiol Clin 2021; 39:353-363. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34247749>
7. Mesi O, Lin C, Ahmed H, Cho LS. Statin intolerance and new lipid-lowering treatments. Cleveland Clinic journal of medicine 2021; 88:381-387. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34210712>
8. Rhainds D, Brodeur MR, Tardif JC. Lipoprotein (a): When to Measure and How to Treat? Curr Atheroscler Rep 2021; 23:51. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34235598>
9. Young RP, Scott RJ. Statins as adjunct therapy in COPD: is it time to target innate immunity and cardiovascular risk? The European respiratory journal 2021; 58. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34326175>
10. Cicero AFG, Fogacci F, Cincione I. Evaluating pharmacokinetics of bempedoic acid in the treatment of hypercholesterolemia. Expert Opin Drug Metab Toxicol 2021:1-7. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34197267>
11. Eisavi M, Mazaheri E, Rezapour A *et al.* The Cost-Effectiveness and Cost-Utility of Statin Drug for the Treatment of Patients with Cardiovascular Disease, A Systematic Review. International journal of preventive medicine 2021; 12:39. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249288>

12. Patel D, Busch R. Omega-3 Fatty Acids and Cardiovascular Disease: A Narrative Review for Pharmacists. Journal of cardiovascular pharmacology and therapeutics 2021;10742484211023715.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34191622>
13. Rogula S, Błażejowska E, Gąsecka A *et al.* Inclisiran-Silencing the Cholesterol, Speaking up the Prognosis. Journal of clinical medicine 2021; 10.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34199468>
14. Tadic M, Sala C, Grassi G *et al.* Omega-3 Fatty Acids and Coronary Artery Disease: More Questions Than Answers. Journal of clinical medicine 2021; 10.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34200081>
15. Jiang W, Hu JW, He XR *et al.* Statins: a repurposed drug to fight cancer. Journal of experimental & clinical cancer research : CR 2021; 40:241.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34303383>
16. Tarar ZI, Zafar MU, Ghous G *et al.* Pravastatin-Induced Acute Pancreatitis: A Case Report and Literature Review. Journal of investigative medicine high impact case reports 2021; 9:23247096211028386.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34180257>
17. Wilkins JT, Lloyd-Jones DM. Novel Lipid-Lowering Therapies to Reduce Cardiovascular Risk. Jama 2021; 326:266-267.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34283191>
18. Jurcau A, Simion A. Cognition, Statins, and Cholesterol in Elderly Ischemic Stroke Patients: A Neurologist's Perspective. Medicina (Kaunas, Lithuania) 2021; 57.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34199243>
19. Huang CT, Liang YJ. Anti-tumor effect of statin on pancreatic adenocarcinoma: From concept to precision medicine. World journal of clinical cases 2021; 9:4500-4505. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34222418>
20. Xu Y, Xiao P, Ba TT *et al.* (Advances and controversies of statins application in prevention and treatment of hepatocellular carcinoma). Zhonghua zhong liu za zhi (Chinese journal of oncology) 2021; 43:751-755.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34289568>

Safety and side effects

1. Peng WY, Huang AC, Ting CT, Tsai TH. Preclinical Pharmacokinetics and Pharmacodynamics of Coptidis Preparation in Combination with Lovastatin in High-Fat Diet-Induced Hyperlipidemic Rats. ACS omega 2021; 6:15804-15815.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34179624>
2. Nabizadeh F, Balabandian M, Sharafi AM *et al.* Statins and risk of amyotrophic lateral sclerosis: a systematic review and meta-analysis. Acta neurologica Belgica 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34322852>
3. Zereshkian A, Waserman S. Liver enzyme elevation and eosinophilia with atorvastatin: a case of probable DRESS without cutaneous symptoms. Allergy Asthma Clin Immunol 2021; 17:81.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34330325>

4. Hou Q, Pang C, Chen Y. Association Between Vitamin D and Statin-Related Myopathy: A Meta-analysis. Am J Cardiovasc Drugs 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34296397>
5. Božina N, Ganoci L, Simičević L *et al.* Drug-drug-gene interactions as mediators of adverse drug reactions to diclofenac and statins: a case report and literature review. Arhiv za higijenu rada i toksikologiju 2021; 72:114-128. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34187111>
6. Janik MJ, Urbach DV, van Nieuwenhuizen E *et al.* Alirocumab treatment and neurocognitive function according to the CANTAB scale in patients at increased cardiovascular risk: A prospective, randomized, placebo-controlled study. Atherosclerosis 2021; 331:20-27. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34303265>
7. Thiermeier N, Lämmer R, Mardin C, Hohberger B. Erlanger Glaucoma Registry: Effect of a Long-Term Therapy with Statins and Acetyl Salicylic Acid on Glaucoma Conversion and Progression. Biology (Basel) 2021; 10. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34208432>
8. Abo-Zalam HB, El-Denshary ES, Abdelsalam RM *et al.* Therapeutic advancement of simvastatin-loaded solid lipid nanoparticles (SV-SLNs) in treatment of hyperlipidemia and attenuating hepatotoxicity, myopathy and apoptosis: Comprehensive study. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2021; 139:111494. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34243595>
9. Cai T, Abel L, Langford O *et al.* Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses. Bmj 2021; 374:n1537. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34261627>
10. Abudalou M, Mohamed AS, Vega EA, Al Sbihi A. Colchicine-induced rhabdomyolysis: a review of 83 cases. BMJ case reports 2021; 14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34290008>
11. Petreski T, Piko N, Petrijan T *et al.* Statin-Associated Necrotizing Myopathy Leading to Acute Kidney Injury: A Case Report. Case Rep Nephrol Dial 2021; 11:129-135. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250030>
12. Mesi O, Lin C, Ahmed H, Cho LS. Statin intolerance and new lipid-lowering treatments. Cleveland Clinic journal of medicine 2021; 88:381-387. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34210712>
13. Skajaa N, Bakos I, Horváth-Puhó E *et al.* Statin Initiation and Risk of Amyotrophic Lateral Sclerosis: A Danish Population-based Cohort Study. Epidemiology 2021; 32:756-762. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34183532>
14. Bibi M, Ferro A, Guimarães F *et al.* When Should Statins Be Stopped? European journal of case reports in internal medicine 2021; 8:002661. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268273>
15. Lorenzo-Villalba N, Andrès E, Meyer A. Chronic Onset Form of Anti-HMG-CoA Reductase Myopathy. European journal of case reports in internal medicine 2021; 8:002672. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268274>
16. Lv S, Yu H, Liu X, Gao X. The Study on the Mechanism of Huga Tablets in Treating Drug-Induced Liver Injury Induced by Atorvastatin. Frontiers in pharmacology 2021; 12:683707. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34262454>

17. Li Z, Zhang J, Xue Y *et al.* Pitavastatin stimulates retinal angiogenesis via HMG-CoA reductase-independent activation of RhoA-mediated pathways and focal adhesion. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2021; 259:2707-2716. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34328550>
18. Fuah KW, Lim C. First Reported Case of Rhabdomyolysis Associated with Concomitant Use of Cyclosporin, Diltiazem, and Simvastatin. Indian J Nephrol 2021; 31:173-175. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34267441>
19. Nikalji R, Sen S. Rosuvastatin-Induced Rhabdomyolysis: A Case Report. Indian J Nephrol 2021; 31:190-193. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34267446>
20. Fukase T, Dohi T, Kato Y *et al.* High Apolipoprotein E Levels Predict Adverse Limb Events in Patients with Peripheral Artery Disease Due to Peripheral Artery Disease Undergoing Endovascular Treatment and On-Statins Treatment. Int Heart J 2021; 62:872-878. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34276016>
21. Williams B, Horn MP, Banz Y *et al.* Cutaneous involvement in anti-HMGCR positive necrotizing myopathy. J Autoimmun 2021; 123:102691. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34332436>
22. Sun T, Xing HL, Chen ZZ *et al.* Simvastatin reverses the harmful effects of high fat diet on titanium rod osseointegration in ovariectomized rats. J Bone Miner Metab 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34189660>
23. Tarar ZI, Zafar MU, Ghous G *et al.* Pravastatin-Induced Acute Pancreatitis: A Case Report and Literature Review. Journal of investigative medicine high impact case reports 2021; 9:23247096211028386. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34180257>
24. Jayatilaka S, Desai K, Rijal S, Zimmerman D. Statin-Induced Autoimmune Necrotizing Myopathy. J Prim Care Community Health 2021; 12:21501327211028714. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34219515>
25. Gawey B, Tannu M, Rim J *et al.* Statin-Induced Necrotizing Autoimmune Myopathy. JACC Case Rep 2020; 2:440-443. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34317259>
26. Laird J, Falk RH, Coyle M, Cuddy SAM. Rhabdomyolysis in the Setting of Concomitant Use of Tafamidis, Atorvastatin, and Amiodarone. JACC Case Rep 2020; 2:2372-2375. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34317174>
27. Pickett JK, Shah M, Gillette M *et al.* Acute Tubular Injury in a Patient on a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor. JACC Case Rep 2020; 2:1042-1045. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34317411>
28. Jurcau A, Simion A. Cognition, Statins, and Cholesterol in Elderly Ischemic Stroke Patients: A Neurologist's Perspective. Medicina (Kaunas, Lithuania) 2021; 57. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34199243>
29. Rimpelová S, Kolář M, Strnad H *et al.* Comparison of Transcriptomic Profiles of MiaPaCa-2 Pancreatic Cancer Cells Treated with Different Statins. Molecules (Basel, Switzerland) 2021; 26. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34207840>
30. Lee KH, Gao Y, Lau V. Statin-associated anti-3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR) myopathy: Imaging findings on thigh-muscle magnetic resonance imaging (MRI) in six patients. Muscle Nerve 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34297419>

31. Moschetti A, Dagda RK, Ryan RO. Coenzyme Q nanodisks counteract the effect of statins on C2C12 myotubes. Nanomedicine : nanotechnology, biology, and medicine 2021; 37:102439. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256063>
32. Watanabe LM, Navarro AM, Seale LA. Intersection between Obesity, Dietary Selenium, and Statin Therapy in Brazil. Nutrients 2021; 13. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34204631>
33. Meng M, Li X, Zhang X, Sun B. Baicalein inhibits the pharmacokinetics of simvastatin in rats via regulating the activity of CYP3A4. Pharmaceutical biology 2021; 59:880-883. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34214011>
34. Brunette CA, Vassy JL. The role of SLCO1B1 genotyping in lowering cardiovascular risk. Pharmacogenomics 2021; 22:649-656. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34196599>

Stroke and CNS

1. Vogt NM, Hunt JFV, Ma Y *et al.* Effects of simvastatin on white matter integrity in healthy middle-aged adults. Annals of clinical and translational neurology 2021; 8:1656-1667. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34275209>
2. Bohara S, Gaonkar VB, Garg K *et al.* Effect of statins on functional outcome and mortality following aneurysmal subarachnoid hemorrhage - Results of a meta-analysis, metaregression and trial sequential analysis. Clin Neurol Neurosurg 2021; 207:106787. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34225002>
3. Erkol A, Dalgıç Y, Yıldırım S, Turan B. Incidence and predictors of prolonged hemodynamic depression after carotid artery stenting: Yet another benefit of statins? Clin Neurol Neurosurg 2021; 207:106786. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34198224>
4. Hayfron-Benjamin CF, Mosterd C, Maitland-van der Zee AH *et al.* Inflammation and its associations with aortic stiffness, coronary artery disease and peripheral artery disease in different ethnic groups: The HELIUS Study. EClinicalMedicine 2021; 38:101012. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34278285>
5. Skajaa N, Bakos I, Horváth-Puhó E *et al.* Statin Initiation and Risk of Amyotrophic Lateral Sclerosis: A Danish Population-based Cohort Study. Epidemiology 2021; 32:756-762. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34183532>
6. Tomaszewski M, Zolkowska D, Plewa Z *et al.* Effect of acute and chronic exposure to lovastatin on the anticonvulsant action of classical antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Eur J Pharmacol 2021; 907:174290. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34217711>
7. Wang X, Song J, He Q, You C. Pharmacological Treatment in the Management of Chronic Subdural Hematoma. Frontiers in aging neuroscience 2021; 13:684501. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34276343>
8. Lee MC, Peng TR, Chen BL *et al.* Effects of various statins on depressive symptoms: A network meta-analysis. Journal of affective disorders 2021; 293:205-213. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34217957>
9. Squizzato F, Xodo A, Tagliavero J *et al.* Early outcomes of routine delayed shunting in carotid endarterectomy for symptomatic patients. J Cardiovasc Surg (Torino) 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34308613>

10. Wańkowicz P, Staszewski J, Dębiec A *et al.* Pre-Stroke Statin Therapy Improves In-Hospital Prognosis Following Acute Ischemic Stroke Associated with Well-Controlled Nonvalvular Atrial Fibrillation. Journal of clinical medicine 2021; 10. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34300202>
11. Zeki Al Hazzouri A, Jawadekar N, Grasset L *et al.* Statins and cognitive decline in the Cardiovascular Health Study: A comparison of different analytical approaches. J Gerontol A Biol Sci Med Sci 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34331536>
12. Palermo G, Giannoni S, Giuntini M *et al.* Statins in Parkinson's Disease: Influence on Motor Progression. Journal of Parkinson's disease 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34275907>
13. Jurcau A, Simion A. Cognition, Statins, and Cholesterol in Elderly Ischemic Stroke Patients: A Neurologist's Perspective. Medicina (Kaunas, Lithuania) 2021; 57. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34199243>
14. Li C, Bu X, Liu Y. Effect of folic acid combined with pravastatin on arteriosclerosis in elderly hypertensive patients with lacunar infarction. Medicine (Baltimore) 2021; 100:e26540. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34260532>
15. Walker AJ, Kim Y, Borissiouk I *et al.* Statins: Neurobiological underpinnings and mechanisms in mood disorders. Neurosci Biobehav Rev 2021; 128:693-708. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34265321>
16. Jeong SM, Shin DW, Yoo TG *et al.* Association between statin use and Alzheimer's disease with dose response relationship. Scientific reports 2021; 11:15280. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34315986>
17. Correction to: Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Trial. Stroke 2021; 52:e526. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34310183>
18. Whiteley WN, Gupta AK, Godec T *et al.* Long-Term Incidence of Stroke and Dementia in ASCOT. Stroke 2021:Strokeaha120033489. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34192893>

Triglycerides/HDL

1. Fan W, Philip S, Toth PP *et al.* Estimated ASCVD risk according to statin use in US adults with borderline triglycerides: Results from National Health and Nutrition Examination Survey (NHANES) 2007-2014. Am J Prev Cardiol 2020; 3:100087. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34327466>
2. Mazhar J, Figtree G, Vernon ST *et al.* Progression of coronary atherosclerosis in patients without standard modifiable risk factors. Am J Prev Cardiol 2020; 4:100116. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34327476>
3. Liu HH, Li S, Cao YX *et al.* Association of triglyceride-rich lipoprotein-cholesterol with recurrent cardiovascular events in statin-treated patients according to different inflammatory status. Atherosclerosis 2021; 330:29-35. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34225103>
4. Kudinov VA, Torkhovskaya TI, Zakharova TS *et al.* High-density lipoprotein remodeling by phospholipid nanoparticles improves cholesterol efflux capacity and protects from atherosclerosis. Biomedicine & pharmacotherapy = Biomedecine &

- pharmacotherapie 2021; 141:111900.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34328100>
5. Woo JS, Hong SJ, Cha DH *et al.* Comparison of the Efficacy and Safety of Atorvastatin 40 mg/ ω -3 fatty acids 4 g Fixed-Dose Combination and Atorvastatin 40 mg Monotherapy in Hypertriglyceridemic Patients Who Poorly Respond to Atorvastatin 40 mg Monotherapy: An 8-Week, Multicenter, Randomized, Double-Blind Phase III Study. Clinical therapeutics 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34332788>
 6. Pareek M, Mason RP, Bhatt DL. Icosapent ethyl: safely reducing cardiovascular risk in adults with elevated triglycerides. Expert opinion on drug safety 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34253137>
 7. Choi J, Kim H, Jun J *et al.* Recurrent Pancreatitis in a Pregnant Woman with Severe Hypertriglyceridemia Successfully Managed by Multiple Plasmapheresis. J Atheroscler Thromb 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34219115>
 8. Kapoor K, Alfaddagh A, Stone NJ, Blumenthal RS. Update on the omega-3 fatty acid trial landscape: A narrative review with implications for primary prevention. J Clin Lipidol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34294561>
 9. Alvarez-Jimenez L, Moreno-Cabañas A, Ramirez-Jimenez M *et al.* Effectiveness of statins vs. exercise on reducing postprandial hypertriglyceridemia in dyslipidemic population: A systematic review and network meta-analysis. J Sport Health Sci 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34298253>

Trials

1. Oh PC, Jang AY, Ha K *et al.* Effect of Atorvastatin (10 mg) and Ezetimibe (10 mg) Combination Compared to Atorvastatin (40 mg) Alone on Coronary Atherosclerosis. Am J Cardiol 2021; 154:22-28.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34238445>
2. Nelson AJ, Puri R, Brennan DM *et al.* C-reactive protein levels and plaque regression with evolocumab: Insights from GLAGOV. Am J Prev Cardiol 2020; 3:100091. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34327467>
3. Vogt NM, Hunt JFV, Ma Y *et al.* Effects of simvastatin on white matter integrity in healthy middle-aged adults. Annals of clinical and translational neurology 2021; 8:1656-1667. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34275209>
4. Janik MJ, Urbach DV, van Nieuwenhuizen E *et al.* Alirocumab treatment and neurocognitive function according to the CANTAB scale in patients at increased cardiovascular risk: A prospective, randomized, placebo-controlled study. Atherosclerosis 2021; 331:20-27.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34303265>
5. Renkens MPL, Mintz GS, Torguson R *et al.* Non-culprit MACE-rate in LRP: The influence of optimal medical therapy using DAPT and statins. Cardiovascular revascularization medicine : including molecular interventions 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34303625>
6. Murtola TJ, Siltari A. Statins for Prostate Cancer: When and How Much? Clin Cancer Res 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34281913>

7. Erkol A, Dalgıç Y, Yıldırım S, Turan B. Incidence and predictors of prolonged hemodynamic depression after carotid artery stenting: Yet another benefit of statins? Clin Neurol Neurosurg 2021; 207:106786. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34198224>
8. Woo JS, Hong SJ, Cha DH *et al.* Comparison of the Efficacy and Safety of Atorvastatin 40 mg/ ω -3 fatty acids 4 g Fixed-Dose Combination and Atorvastatin 40 mg Monotherapy in Hypertriglyceridemic Patients Who Poorly Respond to Atorvastatin 40 mg Monotherapy: An 8-Week, Multicenter, Randomized, Double-Blind Phase III Study. Clinical therapeutics 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34332788>
9. Hu J, Yang C, Yang G *et al.* Effects of atorvastatin doses on serum level of procalcitonin and predictors for major adverse cardiovascular events in patients with acute myocardial infarction: a pilot study and post hoc analysis. Coronary artery disease 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34292180>
10. Al Salman M, Ghiasi M, Farid AS *et al.* Oral simvastatin combined with narrowband UVB for the treatment of psoriasis: A randomized controlled trial. Dermatologic therapy 2021:e15075. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34327798>
11. Luchsinger JA, Younes N, Manly JJ *et al.* Association of Glycemia, Lipids, and Blood Pressure With Cognitive Performance in People With Type 2 Diabetes in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study. Diabetes Care 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34285097>
12. Sever P, Gouni-Berthold I, Keech A *et al.* LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial. Eur J Prev Cardiol 2021; 28:805-812. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34298555>
13. Schwartz GG, Szarek M, Bittner VA *et al.* Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. J Am Coll Cardiol 2021; 78:421-433. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34325831>
14. Handayani W, Suharjo, Yogiarto M. Analysis of HMGB-1 level before and after providing atorvastatin standard therapy in coronary artery disease patients with type-2 diabetes mellitus compared to without type-2 diabetes mellitus. Journal of basic and clinical physiology and pharmacology 2021; 32:439-446. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34214372>
15. Kapoor K, Alfaddagh A, Stone NJ, Blumenthal RS. Update on the omega-3 fatty acid trial landscape: A narrative review with implications for primary prevention. J Clin Lipidol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34294561>
16. Alvarez-Jimenez L, Moreno-Cabañas A, Ramirez-Jimenez M *et al.* Effectiveness of statins vs. exercise on reducing postprandial hypertriglyceridemia in dyslipidemic population: A systematic review and network meta-analysis. J Sport Health Sci 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34298253>
17. Morgan DJ, Pineles L, Owczarzak J *et al.* Clinician Conceptualization of the Benefits of Treatments for Individual Patients. JAMA network open 2021; 4:e2119747. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34287630>
18. Zvizdić F, Begić E, Dilić M *et al.* Effect of atorvastatin on systolic and diastolic function in patients with heart failure with reduced ejection fraction (HFrEF). Medicinski glasnik : official publication of the Medical Association of

- Zenica-Doboj Canton, Bosnia and Herzegovina 2021; 18.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34212706>
19. Kwon OC, Park YB, Park MC. Effect of statins on the prevention of recurrent thrombosis in thrombotic antiphospholipid syndrome. Rheumatology (Oxford) 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34289012>
 20. Correction to: Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Trial. Stroke 2021; 52:e526.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34310183>
 21. Whiteley WN, Gupta AK, Godec T *et al.* Long-Term Incidence of Stroke and Dementia in ASCOT. Stroke 2021:Strokeaha120033489.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34192893>
 22. Sharma A, Sharma C, Raina S *et al.* A randomized open-label trial to evaluate the efficacy and safety of triple therapy with aspirin, atorvastatin, and nicorandil in hospitalised patients with SARS Cov-2 infection: A structured summary of a study protocol for a randomized controlled trial. Trials 2021; 22:451.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34266452>

Women and elderly

1. Elder P, Sharma G, Gulati M, Michos ED. Identification of female-specific risk enhancers throughout the lifespan of women to improve cardiovascular disease prevention. Am J Prev Cardiol 2020; 2:100028.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34327455>
2. Okunrintemi V, Benson EA, Derbal O *et al.* Age-specific differences in patient reported outcomes among adults with atherosclerotic cardiovascular disease: Medical expenditure panel survey 2006-2015. Am J Prev Cardiol 2020; 3:100083.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34327463>
3. Boccara F. Never too old for lipid-lowering therapy. Arch Cardiovasc Dis 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34257047>
4. Seppala LJ, van de Loo B, Schut M *et al.* A Propensity Score Matched Approach to Assess the Associations of Commonly Prescribed Medications with Fall Risk in a Large Harmonized Cohort of Older Ambulatory Persons. Drugs Aging 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34224104>
5. Skajaa N, Bakos I, Horváth-Puhó E *et al.* Statin Initiation and Risk of Amyotrophic Lateral Sclerosis: A Danish Population-based Cohort Study. Epidemiology 2021; 32:756-762. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34183532>
6. Dardano A, Daniele G, Penno G *et al.* Breaking Therapeutic Inertia With Alirocumab in an 80-Year-Old Patient With Severe Hypercholesterolemia: A Case Report. Frontiers in medicine 2021; 8:699477.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34307425>
7. Choi J, Kim H, Jun J *et al.* Recurrent Pancreatitis in a Pregnant Woman with Severe Hypertriglyceridemia Successfully Managed by Multiple Plasmapheresis. J Atheroscler Thromb 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34219115>
8. Li C, Bu X, Liu Y. Effect of folic acid combined with pravastatin on arteriosclerosis in elderly hypertensive patients with lacunar infarction. Medicine (Baltimore) 2021; 100:e26540. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34260532>

9. Shufelt CL. Statin therapy in midlife women. *Menopause (New York, N.Y.)* 2021; 28:1067-1069. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34284431>

The IAS Statin Newsletter is part of the IAS News and Literature update service.

This activity is supported by an educational grant from Viatrix.
© P.J. Lansberg